

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
11 August 2005 (11.08.2005)

PCT

(10) International Publication Number
WO 2005/073725 A1

- (51) International Patent Classification⁷: **G01N 33/53**, 33/566
- (74) Agents: **SHAYESTEH, Laleh** et al.; Exelixis, Inc., P.O. Box 511, 170 Harbor Way, South San Francisco, California 94083-0511 (US).
- (21) International Application Number:
PCT/US2005/003483
- (22) International Filing Date: 27 January 2005 (27.01.2005)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/539,837 28 January 2004 (28.01.2004) US
- (71) Applicants (for all designated States except US): **EX-ELIXIS, INC** [US/US]; 170 Harbor Way, P. O. Box 511, South San Francisco, California 94083-0511 (US). **HEUER, Timothy S.** [US/US]; 581A Paloma Avenue, Pacifica, California 94044 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **FRIEDMAN, Lori** [US/US]; 113 Arundel Road, San Carlos, California 94070 (US). **FRANCIS-LANG, Helen** [GB/US]; 1782 Pacific Avenue, #2, San Francisco, California 94109 (US). **PARKS, Annette** [US/US]; 83 Clifton Avenue, San Francisco, California 94109 (US). **SHAW, Kenneth James** [US/US]; 484 Sierra Point Road, Brisbane, California 94005 (US). **ZHANG, HaiGuang** [US/US]; 4833 El Grande Place, El Sobrante, California 94803 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: MAN2AS AS MODIFIERS OF THE IGER PATHWAY AND METHODS OF USE

(57) Abstract: Human MAN2A genes are identified as modulators of the IGFR pathway and thus are therapeutic targets for disorders associated with defective IGFR function Methods for identifying modulators of IGFR comprising screening for agents that modulate the activity of MAN2A are provided

WO 2005/073725 A1

MAN2AS AS MODIFIERS OF THE IGFR PATHWAY AND METHODS OF USE

REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. provisional patent application 60/539,837 filed 1/28/2004. The contents of the prior application are hereby incorporated in their entirety.

BACKGROUND OF THE INVENTION

[0002] Somatic mutations in the PTEN (Phosphatase and Tensin homolog deleted on chromosome 10) gene are known to cause tumors in a variety of human tissues. In addition, germline mutations in PTEN are the cause of human diseases (Cowden disease and Bannayan-Zonana syndrome) associated with increased risk of breast and thyroid cancer (Nelen MR et al. (1997) Hum Mol Genet, 8:1383-1387; Liaw D et al. (1997) Nat Genet, 1:64-67; Marsh DJ et al. (1998) Hum Mol Genet, 3:507-515). PTEN is thought to act as a tumor suppressor by regulating several signaling pathways through the second messenger phosphatidylinositol 3,4,5 triphosphate (PIP3). PTEN dephosphorylates the D3 position of PIP3 and downregulates signaling events dependent on PIP3 levels (Maehama T and Dixon JE (1998) J Biol Chem, 273:13375-8). In particular, pro-survival pathways downstream of the insulin-like growth factor (IGF) pathway are regulated by PTEN activity. Stimulation of the IGF pathway, or loss of PTEN function, elevates PIP3 levels and activates pro-survival pathways associated with tumorigenesis (Stambolic V et al. (1998) Cell, 95:29-39). Consistent with this model, elevated levels of insulin-like growth factors I and II correlate with increased risk of cancer (Yu H et al (1999) J Natl Cancer Inst 91:151-156) and poor prognosis (Takanami I et al, 1996, J Surg Oncol 61(3):205-8). In addition, increased levels or activity of positive effectors of the IGF pathway, such as Akt and PI(3) kinase, have been implicated in several types of human cancer (Nicholson KM and Anderson NG (2002) Cellular Signalling, 14:381-395).

[0003] In *Drosophila melanogaster*, as in vertebrates, the Insulin Growth Factor Receptor (IGFR) pathway includes the positive effectors PI(3) kinase, Akt, and PDK and the inhibitor, PTEN. These proteins have been implicated in multiple processes, including the regulation of cell growth and size as well as cell division and survival (Oldham S and Hafen E. (2003) Trends Cell Biol. 13:79-85; Garafolo RS. (2002) Trends Endocr. Metab. 13:156-162; Backman SA et al. (2002) Curr. Op. Neurobio. 12:1-7; Tapon N et al. (2001)

Curr Op. Cell Biol. 13:731-737). Activation of the pathway in *Drosophila* can result in increases in cell size, cell number and organ size (Oldham S et al. (2002) Dev. 129:4103-4109; Prober DA and Edgar BA. (2002) Genes&Dev. 16:2286-2299; Potter CJ et al. (2001) Cell 105:357-368; Verdu J et al. (1999) Cell Biol. 1:500-506).

[0004] Alpha-mannosidase II A (MAN2A), member of the glycosyl hydrolase family, is a Golgi enzyme that catalyzes the final hydrolytic step in the asparagine-linked oligosaccharide (N-glycan) maturation pathway, acting as the committed step in the conversion of high mannose to complex type structures. Mutations in the mouse homolog of MAN2A1 lead to a systemic autoimmune disease similar to human systemic lupus erythematosus. Mutations in the MAN2A2 gene in the male mice results in their infertility.

[0005] The ability to manipulate the genomes of model organisms such as *Drosophila* provides a powerful means to analyze biochemical processes that, due to significant evolutionary conservation, have direct relevance to more complex vertebrate organisms. Due to a high level of gene and pathway conservation, the strong similarity of cellular processes, and the functional conservation of genes between these model organisms and mammals, identification of the involvement of novel genes in particular pathways and their functions in such model organisms can directly contribute to the understanding of the correlative pathways and methods of modulating them in mammals (see, for example, Mechler BM et al., 1985 EMBO J 4:1551-1557; Gateff E. 1982 Adv. Cancer Res. 37: 33-74; Watson KL., et al., 1994 J Cell Sci. 18: 19-33; Miklos GL, and Rubin GM. 1996 Cell 86:521-529; Wassarman DA, et al., 1995 Curr Opin Gen Dev 5: 44-50; and Booth DR. 1999 Cancer Metastasis Rev. 18: 261-284). For example, a genetic screen can be carried out in an invertebrate model organism having underexpression (e.g. knockout) or overexpression of a gene (referred to as a "genetic entry point") that yields a visible phenotype. Additional genes are mutated in a random or targeted manner. When a gene mutation changes the original phenotype caused by the mutation in the genetic entry point, the gene is identified as a "modifier" involved in the same or overlapping pathway as the genetic entry point. When the genetic entry point is an ortholog of a human gene implicated in a disease pathway, such as IGFR, modifier genes can be identified that may be attractive candidate targets for novel therapeutics.

[0006] All references cited herein, including patents, patent applications, publications, and sequence information in referenced Genbank identifier numbers, are incorporated herein in their entireties.

SUMMARY OF THE INVENTION

[0007] We have discovered genes that modify the IGFR pathway in *Drosophila*, and identified their human orthologs, hereinafter referred to as Alpha-mannosidase II A (MAN2A). The invention provides methods for utilizing these IGFR modifier genes and polypeptides to identify MAN2A-modulating agents that are candidate therapeutic agents that can be used in the treatment of disorders associated with defective or impaired IGFR function and/or MAN2A function. Preferred MAN2A-modulating agents specifically bind to MAN2A polypeptides and restore IGFR function. Other preferred MAN2A-modulating agents are nucleic acid modulators such as antisense oligomers and RNAi that repress MAN2A gene expression or product activity by, for example, binding to and inhibiting the respective nucleic acid (i.e. DNA or mRNA).

[0008] MAN2A modulating agents may be evaluated by any convenient *in vitro* or *in vivo* assay for molecular interaction with a MAN2A polypeptide or nucleic acid. In one embodiment, candidate MAN2A modulating agents are tested with an assay system comprising a MAN2A polypeptide or nucleic acid. Agents that produce a change in the activity of the assay system relative to controls are identified as candidate IGFR modulating agents. The assay system may be cell-based or cell-free. MAN2A-modulating agents include MAN2A related proteins (e.g. dominant negative mutants, and biotherapeutics); MAN2A -specific antibodies; MAN2A -specific antisense oligomers and other nucleic acid modulators; and chemical agents that specifically bind to or interact with MAN2A or compete with MAN2A binding partner (e.g. by binding to a MAN2A binding partner). In one specific embodiment, a small molecule modulator is identified using a hydrolase assay. In specific embodiments, the screening assay system is selected from a binding assay, an apoptosis assay, a cell proliferation assay, an angiogenesis assay, and a hypoxic induction assay.

[0009] In another embodiment, candidate IGFR pathway modulating agents are further tested using a second assay system that detects changes in the IGFR pathway, such as angiogenic, apoptotic, or cell proliferation changes produced by the originally identified candidate agent or an agent derived from the original agent. The second assay system may use cultured cells or non-human animals. In specific embodiments, the secondary assay system uses non-human animals, including animals predetermined to have a disease or disorder implicating the IGFR pathway, such as an angiogenic, apoptotic, or cell proliferation disorder (e.g. cancer).

[0010] The invention further provides methods for modulating the MAN2A function and/or the IGFR pathway in a mammalian cell by contacting the mammalian cell with an agent that specifically binds a MAN2A polypeptide or nucleic acid. The agent may be a small molecule modulator, a nucleic acid modulator, or an antibody and may be administered to a mammalian animal predetermined to have a pathology associated with the IGFR pathway.

DETAILED DESCRIPTION OF THE INVENTION

[0011] A dominant loss of function screen was carried out in *Drosophila* to identify genes that interact with or modulate the IGFR signaling pathway. Modifiers of the IGFR pathway and their orthologs were identified. The CG4606 (Alpha-man-IIb) gene was identified as a modifier of the IGFR pathway. Accordingly, vertebrate orthologs of these modifiers, and preferably the human orthologs, MAN2A genes (i.e., nucleic acids and polypeptides) are attractive drug targets for the treatment of pathologies associated with a defective IGFR signaling pathway, such as cancer.

[0012] In vitro and in vivo methods of assessing MAN2A function are provided herein. Modulation of the MAN2A or their respective binding partners is useful for understanding the association of the IGFR pathway and its members in normal and disease conditions and for developing diagnostics and therapeutic modalities for IGFR related pathologies. MAN2A-modulating agents that act by inhibiting or enhancing MAN2A expression, directly or indirectly, for example, by affecting a MAN2A function such as enzymatic (e.g., catalytic) or binding activity, can be identified using methods provided herein. MAN2A modulating agents are useful in diagnosis, therapy and pharmaceutical development.

Nucleic acids and polypeptides of the invention

[0013] Sequences related to MAN2A nucleic acids and polypeptides that can be used in the invention are disclosed in Genbank (referenced by Genbank identifier (GI) number) as GI#s 4758697 (SEQ ID NO:1), 1117826 (SEQ ID NO:2), 21734129 (SEQ ID NO:3), and 5540099 (SEQ ID NO:4) for nucleic acid, and GI#s 4758698 (SEQ ID NO:5) and 3123244 (SEQ ID NO:6) for polypeptide sequences.

[0014] The term "MAN2A polypeptide" refers to a full-length MAN2A protein or a functionally active fragment or derivative thereof. A "functionally active" MAN2A fragment or derivative exhibits one or more functional activities associated with a full-

length, wild-type MAN2A protein, such as antigenic or immunogenic activity, enzymatic activity, ability to bind natural cellular substrates, etc. The functional activity of MAN2A proteins, derivatives and fragments can be assayed by various methods known to one skilled in the art (Current Protocols in Protein Science (1998) Coligan *et al.*, eds., John Wiley & Sons, Inc., Somerset, New Jersey) and as further discussed below. In one embodiment, a functionally active MAN2A polypeptide is a MAN2A derivative capable of rescuing defective endogenous MAN2A activity, such as in cell based or animal assays; the rescuing derivative may be from the same or a different species. For purposes herein, functionally active fragments also include those fragments that comprise one or more structural domains of a MAN2A, such as a binding domain. Protein domains can be identified using the PFAM program (Bateman A., et al., Nucleic Acids Res, 1999, 27:260-2). For example, the Glycosyl hydrolases family 38 N-terminus domain (PFAM 01074) of MAN2A from GIs# 4758698 and 3123244 (SEQ ID NOs:5 and 6, respectively) is located respectively at approximately amino acid residues 167 to 498 and 167 to 498. Also, the Glycosyl hydrolases family 38 C-terminus domain (PFAM 07748) of MAN2A from GIs# 4758698 and 3123244 (SEQ ID NOs:5 and 6, respectively) is located respectively at approximately amino acid residues 648 to 1139 and 648 to 1135. Methods for obtaining MAN2A polypeptides are also further described below. In some embodiments, preferred fragments are functionally active, domain-containing fragments comprising at least 25 contiguous amino acids, preferably at least 50, more preferably 75, and most preferably at least 100 contiguous amino acids of a MAN2A. In further preferred embodiments, the fragment comprises the entire functionally active domain.

[0015] The term "MAN2A nucleic acid" refers to a DNA or RNA molecule that encodes a MAN2A polypeptide. Preferably, the MAN2A polypeptide or nucleic acid or fragment thereof is from a human, but can also be an ortholog, or derivative thereof with at least 70% sequence identity, preferably at least 80%, more preferably 85%, still more preferably 90%, and most preferably at least 95% sequence identity with human MAN2A. Methods of identifying orthologs are known in the art. Normally, orthologs in different species retain the same function, due to presence of one or more protein motifs and/or 3-dimensional structures. Orthologs are generally identified by sequence homology analysis, such as BLAST analysis, usually using protein bait sequences. Sequences are assigned as a potential ortholog if the best hit sequence from the forward BLAST result retrieves the original query sequence in the reverse BLAST (Huynen MA and Bork P, Proc Natl Acad Sci (1998) 95:5849-5856; Huynen MA *et al.*, Genome Research (2000)

10:1204-1210). Programs for multiple sequence alignment, such as CLUSTAL (Thompson JD et al, 1994, Nucleic Acids Res 22:4673-4680) may be used to highlight conserved regions and/or residues of orthologous proteins and to generate phylogenetic trees. In a phylogenetic tree representing multiple homologous sequences from diverse species (e.g., retrieved through BLAST analysis), orthologous sequences from two species generally appear closest on the tree with respect to all other sequences from these two species. Structural threading or other analysis of protein folding (e.g., using software by ProCeryon, Biosciences, Salzburg, Austria) may also identify potential orthologs. In evolution, when a gene duplication event follows speciation, a single gene in one species, such as *Drosophila*, may correspond to multiple genes (paralogs) in another, such as human. As used herein, the term “orthologs” encompasses paralogs. As used herein, “percent (%) sequence identity” with respect to a subject sequence, or a specified portion of a subject sequence, is defined as the percentage of nucleotides or amino acids in the candidate derivative sequence identical with the nucleotides or amino acids in the subject sequence (or specified portion thereof), after aligning the sequences and introducing gaps, if necessary to achieve the maximum percent sequence identity, as generated by the program WU-BLAST-2.0a19 (Altschul *et al.*, J. Mol. Biol. (1997) 215:403-410) with all the search parameters set to default values. The HSP S and HSP S2 parameters are dynamic values and are established by the program itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of interest is being searched. A % identity value is determined by the number of matching identical nucleotides or amino acids divided by the sequence length for which the percent identity is being reported. “Percent (%) amino acid sequence similarity” is determined by doing the same calculation as for determining % amino acid sequence identity, but including conservative amino acid substitutions in addition to identical amino acids in the computation.

[0016] A conservative amino acid substitution is one in which an amino acid is substituted for another amino acid having similar properties such that the folding or activity of the protein is not significantly affected. Aromatic amino acids that can be substituted for each other are phenylalanine, tryptophan, and tyrosine; interchangeable hydrophobic amino acids are leucine, isoleucine, methionine, and valine; interchangeable polar amino acids are glutamine and asparagine; interchangeable basic amino acids are arginine, lysine and histidine; interchangeable acidic amino acids are aspartic acid and glutamic acid; and interchangeable small amino acids are alanine, serine, threonine, cysteine and glycine.

[0017] Alternatively, an alignment for nucleic acid sequences is provided by the local homology algorithm of Smith and Waterman (Smith and Waterman, 1981, *Advances in Applied Mathematics* 2:482-489; database: European Bioinformatics Institute; Smith and Waterman, 1981, *J. of Molec.Biol.*, 147:195-197; Nicholas et al., 1998, "A Tutorial on Searching Sequence Databases and Sequence Scoring Methods" (www.psc.edu) and references cited therein.; W.R. Pearson, 1991, *Genomics* 11:635-650). This algorithm can be applied to amino acid sequences by using the scoring matrix developed by Dayhoff (Dayhoff: *Atlas of Protein Sequences and Structure*, M. O. Dayhoff ed., 5 suppl. 3:353-358, National Biomedical Research Foundation, Washington, D.C., USA), and normalized by Gribskov (Gribskov 1986 *Nucl. Acids Res.* 14(6):6745-6763). The Smith-Waterman algorithm may be employed where default parameters are used for scoring (for example, gap open penalty of 12, gap extension penalty of two). From the data generated, the "Match" value reflects "sequence identity."

[0018] Derivative nucleic acid molecules of the subject nucleic acid molecules include sequences that hybridize to the nucleic acid sequence of a MAN2A. The stringency of hybridization can be controlled by temperature, ionic strength, pH, and the presence of denaturing agents such as formamide during hybridization and washing. Conditions routinely used are set out in readily available procedure texts (*e.g.*, *Current Protocol in Molecular Biology*, Vol. 1, Chap. 2.10, John Wiley & Sons, Publishers (1994); Sambrook *et al.*, *Molecular Cloning*, Cold Spring Harbor (1989)). In some embodiments, a nucleic acid molecule of the invention is capable of hybridizing to a nucleic acid molecule containing the nucleotide sequence of a MAN2A under high stringency hybridization conditions that are: prehybridization of filters containing nucleic acid for 8 hours to overnight at 65° C in a solution comprising 6X single strength citrate (SSC) (1X SSC is 0.15 M NaCl, 0.015 M Na citrate; pH 7.0), 5X Denhardt's solution, 0.05% sodium pyrophosphate and 100 µg/ml herring sperm DNA; hybridization for 18-20 hours at 65° C in a solution containing 6X SSC, 1X Denhardt's solution, 100 µg/ml yeast tRNA and 0.05% sodium pyrophosphate; and washing of filters at 65° C for 1h in a solution containing 0.1X SSC and 0.1% SDS (sodium dodecyl sulfate).

[0019] In other embodiments, moderately stringent hybridization conditions are used that are: pretreatment of filters containing nucleic acid for 6 h at 40° C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH7.5), 5mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 µg/ml denatured salmon sperm DNA; hybridization for 18-20h at 40° C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH7.5),

5mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 μ g/ml salmon sperm DNA, and 10% (wt/vol) dextran sulfate; followed by washing twice for 1 hour at 55° C in a solution containing 2X SSC and 0.1% SDS.

[0020] Alternatively, low stringency conditions can be used that are: incubation for 8 hours to overnight at 37° C in a solution comprising 20% formamide, 5 x SSC, 50 mM sodium phosphate (pH 7.6), 5X Denhardt's solution, 10% dextran sulfate, and 20 μ g/ml denatured sheared salmon sperm DNA; hybridization in the same buffer for 18 to 20 hours; and washing of filters in 1 x SSC at about 37° C for 1 hour.

Isolation, Production, Expression, and Mis-expression of MAN2A Nucleic Acids and Polypeptides

[0021] MAN2A nucleic acids and polypeptides are useful for identifying and testing agents that modulate MAN2A function and for other applications related to the involvement of MAN2A in the IGFR pathway. MAN2A nucleic acids and derivatives and orthologs thereof may be obtained using any available method. For instance, techniques for isolating cDNA or genomic DNA sequences of interest by screening DNA libraries or by using polymerase chain reaction (PCR) are well known in the art. In general, the particular use for the protein will dictate the particulars of expression, production, and purification methods. For instance, production of proteins for use in screening for modulating agents may require methods that preserve specific biological activities of these proteins, whereas production of proteins for antibody generation may require structural integrity of particular epitopes. Expression of proteins to be purified for screening or antibody production may require the addition of specific tags (*e.g.*, generation of fusion proteins). Overexpression of a MAN2A protein for assays used to assess MAN2A function, such as involvement in cell cycle regulation or hypoxic response, may require expression in eukaryotic cell lines capable of these cellular activities. Techniques for the expression, production, and purification of proteins are well known in the art; any suitable means therefore may be used (*e.g.*, Higgins SJ and Hames BD (eds.) *Protein Expression: A Practical Approach*, Oxford University Press Inc., New York 1999; Stanbury PF et al., *Principles of Fermentation Technology*, 2nd edition, Elsevier Science, New York, 1995; Doonan S (ed.) *Protein Purification Protocols*, Humana Press, New Jersey, 1996; Coligan JE et al, *Current Protocols in Protein Science* (eds.), 1999, John Wiley & Sons, New York). In particular embodiments, recombinant MAN2A is expressed in a cell line known

to have defective IGFR function. The recombinant cells are used in cell-based screening assay systems of the invention, as described further below.

[0022] The nucleotide sequence encoding a MAN2A polypeptide can be inserted into any appropriate expression vector. The necessary transcriptional and translational signals, including promoter/enhancer element, can derive from the native MAN2A gene and/or its flanking regions or can be heterologous. A variety of host-vector expression systems may be utilized, such as mammalian cell systems infected with virus (*e.g.* vaccinia virus, adenovirus, *etc.*); insect cell systems infected with virus (*e.g.* baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, plasmid, or cosmid DNA. An isolated host cell strain that modulates the expression of, modifies, and/or specifically processes the gene product may be used.

[0023] To detect expression of the MAN2A gene product, the expression vector can comprise a promoter operably linked to a MAN2A gene nucleic acid, one or more origins of replication, and, one or more selectable markers (*e.g.* thymidine kinase activity, resistance to antibiotics, *etc.*). Alternatively, recombinant expression vectors can be identified by assaying for the expression of the MAN2A gene product based on the physical or functional properties of the MAN2A protein in *in vitro* assay systems (*e.g.* immunoassays).

[0024] The MAN2A protein, fragment, or derivative may be optionally expressed as a fusion, or chimeric protein product (i.e. it is joined via a peptide bond to a heterologous protein sequence of a different protein), for example to facilitate purification or detection. A chimeric product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other using standard methods and expressing the chimeric product. A chimeric product may also be made by protein synthetic techniques, *e.g.* by use of a peptide synthesizer (Hunkapiller *et al.*, Nature (1984) 310:105-111).

[0025] Once a recombinant cell that expresses the MAN2A gene sequence is identified, the gene product can be isolated and purified using standard methods (*e.g.* ion exchange, affinity, and gel exclusion chromatography; centrifugation; differential solubility; electrophoresis). Alternatively, native MAN2A proteins can be purified from natural sources, by standard methods (*e.g.* immunoaffinity purification). Once a protein is obtained, it may be quantified and its activity measured by appropriate methods, such as immunoassay, bioassay, or other measurements of physical properties, such as crystallography.

[0026] The methods of this invention may also use cells that have been engineered for altered expression (mis-expression) of MAN2A or other genes associated with the IGFR pathway. As used herein, mis-expression encompasses ectopic expression, over-expression, under-expression, and non-expression (*e.g.* by gene knock-out or blocking expression that would otherwise normally occur).

Genetically modified animals

[0027] Animal models that have been genetically modified to alter MAN2A expression may be used in *in vivo* assays to test for activity of a candidate IGFR modulating agent, or to further assess the role of MAN2A in an IGFR pathway process such as apoptosis or cell proliferation. Preferably, the altered MAN2A expression results in a detectable phenotype, such as decreased or increased levels of cell proliferation, angiogenesis, or apoptosis compared to control animals having normal MAN2A expression. The genetically modified animal may additionally have altered IGFR expression (*e.g.* IGFR knockout). Preferred genetically modified animals are mammals such as primates, rodents (preferably mice or rats), among others. Preferred non-mammalian species include zebrafish, *C. elegans*, and *Drosophila*. Preferred genetically modified animals are transgenic animals having a heterologous nucleic acid sequence present as an extrachromosomal element in a portion of its cells, *i.e.* mosaic animals (see, for example, techniques described by Jakobovits, 1994, *Curr. Biol.* 4:761-763.) or stably integrated into its germ line DNA (*i.e.*, in the genomic sequence of most or all of its cells). Heterologous nucleic acid is introduced into the germ line of such transgenic animals by genetic manipulation of, for example, embryos or embryonic stem cells of the host animal.

[0028] Methods of making transgenic animals are well-known in the art (for transgenic mice see Brinster *et al.*, *Proc. Nat. Acad. Sci. USA* 82: 4438-4442 (1985), U.S. Pat. Nos. 4,736,866 and 4,870,009, both by Leder *et al.*, U.S. Pat. No. 4,873,191 by Wagner *et al.*, and Hogan, B., *Manipulating the Mouse Embryo*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., (1986); for particle bombardment see U.S. Pat. No., 4,945,050, by Sanford *et al.*; for transgenic *Drosophila* see Rubin and Spradling, *Science* (1982) 218:348-53 and U.S. Pat. No. 4,670,388; for transgenic insects see Berghammer A.J. *et al.*, *A Universal Marker for Transgenic Insects* (1999) *Nature* 402:370-371; for transgenic Zebrafish see Lin S., *Transgenic Zebrafish*, *Methods Mol Biol.* (2000);136:375-3830); for microinjection procedures for fish, amphibian eggs and birds see Houdebine and Chourrout, *Experientia* (1991) 47:897-905; for transgenic rats see Hammer *et al.*, *Cell*

(1990) 63:1099-1112; and for culturing of embryonic stem (ES) cells and the subsequent production of transgenic animals by the introduction of DNA into ES cells using methods such as electroporation, calcium phosphate/DNA precipitation and direct injection see, e.g., *Teratocarcinomas and Embryonic Stem Cells, A Practical Approach*, E. J. Robertson, ed., IRL Press (1987)). Clones of the nonhuman transgenic animals can be produced according to available methods (see Wilmut, I. *et al.* (1997) *Nature* 385:810-813; and PCT International Publication Nos. WO 97/07668 and WO 97/07669).

[0029] In one embodiment, the transgenic animal is a “knock-out” animal having a heterozygous or homozygous alteration in the sequence of an endogenous MAN2A gene that results in a decrease of MAN2A function, preferably such that MAN2A expression is undetectable or insignificant. Knock-out animals are typically generated by homologous recombination with a vector comprising a transgene having at least a portion of the gene to be knocked out. Typically a deletion, addition or substitution has been introduced into the transgene to functionally disrupt it. The transgene can be a human gene (e.g., from a human genomic clone) but more preferably is an ortholog of the human gene derived from the transgenic host species. For example, a mouse MAN2A gene is used to construct a homologous recombination vector suitable for altering an endogenous MAN2A gene in the mouse genome. Detailed methodologies for homologous recombination in mice are available (see Capecchi, *Science* (1989) 244:1288-1292; Joyner *et al.*, *Nature* (1989) 338:153-156). Procedures for the production of non-rodent transgenic mammals and other animals are also available (Houdebine and Chourrout, *supra*; Pursel *et al.*, *Science* (1989) 244:1281-1288; Simms *et al.*, *Bio/Technology* (1988) 6:179-183). In a preferred embodiment, knock-out animals, such as mice harboring a knockout of a specific gene, may be used to produce antibodies against the human counterpart of the gene that has been knocked out (Claesson MH *et al.*, (1994) *Scan J Immunol* 40:257-264; Declerck PJ *et al.*, (1995) *J Biol Chem.* 270:8397-400).

[0030] In another embodiment, the transgenic animal is a “knock-in” animal having an alteration in its genome that results in altered expression (e.g., increased (including ectopic) or decreased expression) of the MAN2A gene, e.g., by introduction of additional copies of MAN2A, or by operatively inserting a regulatory sequence that provides for altered expression of an endogenous copy of the MAN2A gene. Such regulatory sequences include inducible, tissue-specific, and constitutive promoters and enhancer elements. The knock-in can be homozygous or heterozygous.

[0031] Transgenic nonhuman animals can also be produced that contain selected systems allowing for regulated expression of the transgene. One example of such a system that may be produced is the cre/loxP recombinase system of bacteriophage P1 (Lakso *et al.*, PNAS (1992) 89:6232-6236; U.S. Pat. No. 4,959,317). If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of "double" transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase. Another example of a recombinase system is the FLP recombinase system of *Saccharomyces cerevisiae* (O'Gorman *et al.* (1991) Science 251:1351-1355; U.S. Pat. No. 5,654,182). In a preferred embodiment, both Cre-LoxP and Flp-Frt are used in the same system to regulate expression of the transgene, and for sequential deletion of vector sequences in the same cell (Sun X *et al.* (2000) Nat Genet 25:83-6).

[0032] The genetically modified animals can be used in genetic studies to further elucidate the IGFR pathway, as animal models of disease and disorders implicating defective IGFR function, and for *in vivo* testing of candidate therapeutic agents, such as those identified in screens described below. The candidate therapeutic agents are administered to a genetically modified animal having altered MAN2A function and phenotypic changes are compared with appropriate control animals such as genetically modified animals that receive placebo treatment, and/or animals with unaltered MAN2A expression that receive candidate therapeutic agent.

[0033] In addition to the above-described genetically modified animals having altered MAN2A function, animal models having defective IGFR function (and otherwise normal MAN2A function), can be used in the methods of the present invention. For example, an IGFR knockout mouse can be used to assess, *in vivo*, the activity of a candidate IGFR modulating agent identified in one of the *in vitro* assays described below. Preferably, the candidate IGFR modulating agent when administered to a model system with cells defective in IGFR function, produces a detectable phenotypic change in the model system indicating that the IGFR function is restored, i.e., the cells exhibit normal cell cycle progression.

Modulating Agents

[0034] The invention provides methods to identify agents that interact with and/or modulate the function of MAN2A and/or the IGFR pathway. Modulating agents identified by the methods are also part of the invention. Such agents are useful in a variety of diagnostic and therapeutic applications associated with the IGFR pathway, as well as in further analysis of the MAN2A protein and its contribution to the IGFR pathway. Accordingly, the invention also provides methods for modulating the IGFR pathway comprising the step of specifically modulating MAN2A activity by administering a MAN2A-interacting or -modulating agent.

[0035] As used herein, a “MAN2A-modulating agent” is any agent that modulates MAN2A function, for example, an agent that interacts with MAN2A to inhibit or enhance MAN2A activity or otherwise affect normal MAN2A function. MAN2A function can be affected at any level, including transcription, protein expression, protein localization, and cellular or extra-cellular activity. In a preferred embodiment, the MAN2A - modulating agent specifically modulates the function of the MAN2A. The phrases “specific modulating agent”, “specifically modulates”, etc., are used herein to refer to modulating agents that directly bind to the MAN2A polypeptide or nucleic acid, and preferably inhibit, enhance, or otherwise alter, the function of the MAN2A. These phrases also encompass modulating agents that alter the interaction of the MAN2A with a binding partner, substrate, or cofactor (e.g. by binding to a binding partner of a MAN2A, or to a protein/binding partner complex, and altering MAN2A function). In a further preferred embodiment, the MAN2A- modulating agent is a modulator of the IGFR pathway (e.g. it restores and/or upregulates IGFR function) and thus is also an IGFR-modulating agent.

[0036] Preferred MAN2A-modulating agents include small molecule compounds; MAN2A-interacting proteins, including antibodies and other biotherapeutics; and nucleic acid modulators such as antisense and RNA inhibitors. The modulating agents may be formulated in pharmaceutical compositions, for example, as compositions that may comprise other active ingredients, as in combination therapy, and/or suitable carriers or excipients. Techniques for formulation and administration of the compounds may be found in “Remington’s Pharmaceutical Sciences” Mack Publishing Co., Easton, PA, 19th edition.

Small molecule modulators

- [0037] Small molecules are often preferred to modulate function of proteins with enzymatic function, and/or containing protein interaction domains. Chemical agents, referred to in the art as "small molecule" compounds are typically organic, non-peptide molecules, having a molecular weight up to 10,000, preferably up to 5,000, more preferably up to 1,000, and most preferably up to 500 daltons. This class of modulators includes chemically synthesized molecules, for instance, compounds from combinatorial chemical libraries. Synthetic compounds may be rationally designed or identified based on known or inferred properties of the MAN2A protein or may be identified by screening compound libraries. Alternative appropriate modulators of this class are natural products, particularly secondary metabolites from organisms such as plants or fungi, which can also be identified by screening compound libraries for MAN2A-modulating activity. Methods for generating and obtaining compounds are well known in the art (Schreiber SL, Science (2000) 151: 1964-1969; Radmann J and Gunther J, Science (2000) 151:1947-1948).
- [0038] Small molecule modulators identified from screening assays, as described below, can be used as lead compounds from which candidate clinical compounds may be designed, optimized, and synthesized. Such clinical compounds may have utility in treating pathologies associated with the IGFR pathway. The activity of candidate small molecule modulating agents may be improved several-fold through iterative secondary functional validation, as further described below, structure determination, and candidate modulator modification and testing. Additionally, candidate clinical compounds are generated with specific regard to clinical and pharmacological properties. For example, the reagents may be derivatized and re-screened using *in vitro* and *in vivo* assays to optimize activity and minimize toxicity for pharmaceutical development.

Protein Modulators

- [0039] Specific MAN2A-interacting proteins are useful in a variety of diagnostic and therapeutic applications related to the IGFR pathway and related disorders, as well as in validation assays for other MAN2A-modulating agents. In a preferred embodiment, MAN2A-interacting proteins affect normal MAN2A function, including transcription, protein expression, protein localization, and cellular or extra-cellular activity. In another embodiment, MAN2A-interacting proteins are useful in detecting and providing information about the function of MAN2A proteins, as is relevant to IGFR related disorders, such as cancer (e.g., for diagnostic means).

- [0040] A MAN2A-interacting protein may be endogenous, i.e. one that naturally interacts genetically or biochemically with a MAN2A, such as a member of the MAN2A pathway that modulates MAN2A expression, localization, and/or activity. MAN2A-modulators include dominant negative forms of MAN2A-interacting proteins and of MAN2A proteins themselves. Yeast two-hybrid and variant screens offer preferred methods for identifying endogenous MAN2A-interacting proteins (Finley, R. L. et al. (1996) in DNA Cloning-Expression Systems: A Practical Approach, eds. Glover D. & Hames B. D (Oxford University Press, Oxford, England), pp. 169-203; Fashema SF et al., Gene (2000) 250:1-14; Drees BL Curr Opin Chem Biol (1999) 3:64-70; Vidal M and Legrain P Nucleic Acids Res (1999) 27:919-29; and U.S. Pat. No. 5,928,868). Mass spectrometry is an alternative preferred method for the elucidation of protein complexes (reviewed in, e.g., Pandley A and Mann M, Nature (2000) 405:837-846; Yates JR 3rd, Trends Genet (2000) 16:5-8).
- [0041] An MAN2A-interacting protein may be an exogenous protein, such as a MAN2A-specific antibody or a T-cell antigen receptor (see, e.g., Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory; Harlow and Lane (1999) Using antibodies: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press). MAN2A antibodies are further discussed below.
- [0042] In preferred embodiments, a MAN2A-interacting protein specifically binds a MAN2A protein. In alternative preferred embodiments, a MAN2A-modulating agent binds a MAN2A substrate, binding partner, or cofactor.

Antibodies

- [0043] In another embodiment, the protein modulator is a MAN2A specific antibody agonist or antagonist. The antibodies have therapeutic and diagnostic utilities, and can be used in screening assays to identify MAN2A modulators. The antibodies can also be used in dissecting the portions of the MAN2A pathway responsible for various cellular responses and in the general processing and maturation of the MAN2A.
- [0044] Antibodies that specifically bind MAN2A polypeptides can be generated using known methods. Preferably the antibody is specific to a mammalian ortholog of MAN2A polypeptide, and more preferably, to human MAN2A. Antibodies may be polyclonal, monoclonal (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab').sub.2 fragments, fragments produced by a FAb expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. Epitopes of MAN2A which are particularly antigenic can be selected, for example, by

routine screening of MAN2A polypeptides for antigenicity or by applying a theoretical method for selecting antigenic regions of a protein (Hopp and Wood (1981), Proc. Natl. Acad. Sci. U.S.A. 78:3824-28; Hopp and Wood, (1983) Mol. Immunol. 20:483-89; Sutcliffe et al., (1983) Science 219:660-66) to the amino acid sequence of a MAN2A. Monoclonal antibodies with affinities of 10^8 M^{-1} preferably 10^9 M^{-1} to 10^{10} M^{-1} , or stronger can be made by standard procedures as described (Harlow and Lane, *supra*; Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed) Academic Press, New York; and U.S. Pat. Nos. 4,381,292; 4,451,570; and 4,618,577). Antibodies may be generated against crude cell extracts of MAN2A or substantially purified fragments thereof. If MAN2A fragments are used, they preferably comprise at least 10, and more preferably, at least 20 contiguous amino acids of a MAN2A protein. In a particular embodiment, MAN2A-specific antigens and/or immunogens are coupled to carrier proteins that stimulate the immune response. For example, the subject polypeptides are covalently coupled to the keyhole limpet hemocyanin (KLH) carrier, and the conjugate is emulsified in Freund's complete adjuvant, which enhances the immune response. An appropriate immune system such as a laboratory rabbit or mouse is immunized according to conventional protocols.

[0045] The presence of MAN2A-specific antibodies is assayed by an appropriate assay such as a solid phase enzyme-linked immunosorbant assay (ELISA) using immobilized corresponding MAN2A polypeptides. Other assays, such as radioimmunoassays or fluorescent assays might also be used.

[0046] Chimeric antibodies specific to MAN2A polypeptides can be made that contain different portions from different animal species. For instance, a human immunoglobulin constant region may be linked to a variable region of a murine mAb, such that the antibody derives its biological activity from the human antibody, and its binding specificity from the murine fragment. Chimeric antibodies are produced by splicing together genes that encode the appropriate regions from each species (Morrison et al., Proc. Natl. Acad. Sci. (1984) 81:6851-6855; Neuberger et al., Nature (1984) 312:604-608; Takeda et al., Nature (1985) 31:452-454). Humanized antibodies, which are a form of chimeric antibodies, can be generated by grafting complementary-determining regions (CDRs) (Carlos, T. M., J. M. Harlan. 1994. Blood 84:2068-2101) of mouse antibodies into a background of human framework regions and constant regions by recombinant DNA technology (Riechmann LM, et al., 1988 Nature 323: 323-327). Humanized antibodies contain ~10% murine sequences and ~90% human sequences, and thus further

reduce or eliminate immunogenicity, while retaining the antibody specificities (Co MS, and Queen C. 1991 Nature 351: 501-501; Morrison SL. 1992 Ann. Rev. Immun. 10:239-265). Humanized antibodies and methods of their production are well-known in the art (U.S. Pat. Nos. 5,530,101, 5,585,089, 5,693,762, and 6,180,370).

[0047] MAN2A-specific single chain antibodies which are recombinant, single chain polypeptides formed by linking the heavy and light chain fragments of the Fv regions via an amino acid bridge, can be produced by methods known in the art (U.S. Pat. No. 4,946,778; Bird, Science (1988) 242:423-426; Huston et al., Proc. Natl. Acad. Sci. USA (1988) 85:5879-5883; and Ward et al., Nature (1989) 334:544-546).

[0048] Other suitable techniques for antibody production involve in vitro exposure of lymphocytes to the antigenic polypeptides or alternatively to selection of libraries of antibodies in phage or similar vectors (Huse et al., Science (1989) 246:1275-1281). As used herein, T-cell antigen receptors are included within the scope of antibody modulators (Harlow and Lane, 1988, *supra*).

[0049] The polypeptides and antibodies of the present invention may be used with or without modification. Frequently, antibodies will be labeled by joining, either covalently or non-covalently, a substance that provides for a detectable signal, or that is toxic to cells that express the targeted protein (Menard S, et al., Int J. Biol Markers (1989) 4:131-134). A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, fluorescent emitting lanthanide metals, chemiluminescent moieties, bioluminescent moieties, magnetic particles, and the like (U.S. Pat. Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241). Also, recombinant immunoglobulins may be produced (U.S. Pat. No. 4,816,567). Antibodies to cytoplasmic polypeptides may be delivered and reach their targets by conjugation with membrane-penetrating toxin proteins (U.S. Pat. No. 6,086,900).

[0050] When used therapeutically in a patient, the antibodies of the subject invention are typically administered parenterally, when possible at the target site, or intravenously. The therapeutically effective dose and dosage regimen is determined by clinical studies. Typically, the amount of antibody administered is in the range of about 0.1 mg/kg –to about 10 mg/kg of patient weight. For parenteral administration, the antibodies are formulated in a unit dosage injectable form (e.g., solution, suspension, emulsion) in association with a pharmaceutically acceptable vehicle. Such vehicles are inherently

nontoxic and non-therapeutic. Examples are water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Nonaqueous vehicles such as fixed oils, ethyl oleate, or liposome carriers may also be used. The vehicle may contain minor amounts of additives, such as buffers and preservatives, which enhance isotonicity and chemical stability or otherwise enhance therapeutic potential. The antibodies' concentrations in such vehicles are typically in the range of about 1 mg/ml to about 10 mg/ml.

Immunotherapeutic methods are further described in the literature (US Pat. No. 5,859,206; WO0073469).

Specific biotherapeutics

[0051] In a preferred embodiment, a MAN2A-interacting protein may have biotherapeutic applications. Biotherapeutic agents formulated in pharmaceutically acceptable carriers and dosages may be used to activate or inhibit signal transduction pathways. This modulation may be accomplished by binding a ligand, thus inhibiting the activity of the pathway; or by binding a receptor, either to inhibit activation of, or to activate, the receptor. Alternatively, the biotherapeutic may itself be a ligand capable of activating or inhibiting a receptor. Biotherapeutic agents and methods of producing them are described in detail in U.S. Pat. No. 6,146,628.

[0052] When the MAN2A is a ligand, it may be used as a biotherapeutic agent to activate or inhibit its natural receptor. Alternatively, antibodies against MAN2A, as described in the previous section, may be used as biotherapeutic agents.

[0053] When the MAN2A is a receptor, its ligand(s), antibodies to the ligand(s) or the MAN2A itself may be used as biotherapeutics to modulate the activity of MAN2A in the IGFR pathway.

Nucleic Acid Modulators

[0054] Other preferred MAN2A-modulating agents comprise nucleic acid molecules, such as antisense oligomers or double stranded RNA (dsRNA), which generally inhibit MAN2A activity. Preferred nucleic acid modulators interfere with the function of the MAN2A nucleic acid such as DNA replication, transcription, translocation of the MAN2A RNA to the site of protein translation, translation of protein from the MAN2A RNA, splicing of the MAN2A RNA to yield one or more mRNA species, or catalytic activity which may be engaged in or facilitated by the MAN2A RNA.

[0055] In one embodiment, the antisense oligomer is an oligonucleotide that is sufficiently complementary to a MAN2A mRNA to bind to and prevent translation, preferably by binding to the 5' untranslated region. MAN2A-specific antisense oligonucleotides, preferably range from at least 6 to about 200 nucleotides. In some embodiments the oligonucleotide is preferably at least 10, 15, or 20 nucleotides in length. In other embodiments, the oligonucleotide is preferably less than 50, 40, or 30 nucleotides in length. The oligonucleotide can be DNA or RNA or a chimeric mixture or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone. The oligonucleotide may include other appending groups such as peptides, agents that facilitate transport across the cell membrane, hybridization-triggered cleavage agents, and intercalating agents.

[0056] In another embodiment, the antisense oligomer is a phosphothioate morpholino oligomer (PMO). PMOs are assembled from four different morpholino subunits, each of which contain one of four genetic bases (A, C, G, or T) linked to a six-membered morpholine ring. Polymers of these subunits are joined by non-ionic phosphoramidate intersubunit linkages. Details of how to make and use PMOs and other antisense oligomers are well known in the art (e.g. see WO99/18193; Probst JC, Antisense Oligodeoxynucleotide and Ribozyme Design, Methods. (2000) 22(3):271-281; Summerton J, and Weller D. 1997 Antisense Nucleic Acid Drug Dev. :7:187-95; US Pat. No. 5,235,033; and US Pat No. 5,378,841).

[0057] Alternative preferred MAN2A nucleic acid modulators are double-stranded RNA species mediating RNA interference (RNAi). RNAi is the process of sequence-specific, post-transcriptional gene silencing in animals and plants, initiated by double-stranded RNA (dsRNA) that is homologous in sequence to the silenced gene. Methods relating to the use of RNAi to silence genes in *C. elegans*, *Drosophila*, plants, and humans are known in the art (Fire A, et al., 1998 Nature 391:806-811; Fire, A. Trends Genet. 15, 358-363 (1999); Sharp, P. A. RNA interference 2001. Genes Dev. 15, 485-490 (2001); Hammond, S. M., et al., Nature Rev. Genet. 2, 110-1119 (2001); Tuschl, T. Chem. Biochem. 2, 239-245 (2001); Hamilton, A. et al., Science 286, 950-952 (1999); Hammond, S. M., et al., Nature 404, 293-296 (2000); Zamore, P. D., et al., Cell 101, 25-33 (2000); Bernstein, E., et al., Nature 409, 363-366 (2001); Elbashir, S. M., et al., Genes Dev. 15, 188-200 (2001); WO0129058; WO9932619; Elbashir SM, et al., 2001 Nature 411:494-498;

Novina CD and Sharp P. 2004 Nature 430:161-164; Soutschek J et al 2004 Nature 432:173-178).

[0058] Nucleic acid modulators are commonly used as research reagents, diagnostics, and therapeutics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used to elucidate the function of particular genes (see, for example, U.S. Pat. No. 6,165,790). Nucleic acid modulators are also used, for example, to distinguish between functions of various members of a biological pathway. For example, antisense oligomers have been employed as therapeutic moieties in the treatment of disease states in animals and man and have been demonstrated in numerous clinical trials to be safe and effective (Milligan JF, *et al*, Current Concepts in Antisense Drug Design, J Med Chem. (1993) 36:1923-1937; Tonkinson JL *et al.*, Antisense Oligodeoxynucleotides as Clinical Therapeutic Agents, Cancer Invest. (1996) 14:54-65). Accordingly, in one aspect of the invention, a MAN2A-specific nucleic acid modulator is used in an assay to further elucidate the role of the MAN2A in the IGFR pathway, and/or its relationship to other members of the pathway. In another aspect of the invention, a MAN2A-specific antisense oligomer is used as a therapeutic agent for treatment of IGFR-related disease states.

Assay Systems

[0059] The invention provides assay systems and screening methods for identifying specific modulators of MAN2A activity. As used herein, an "assay system" encompasses all the components required for performing and analyzing results of an assay that detects and/or measures a particular event. In general, primary assays are used to identify or confirm a modulator's specific biochemical or molecular effect with respect to the MAN2A nucleic acid or protein. In general, secondary assays further assess the activity of a MAN2A modulating agent identified by a primary assay and may confirm that the modulating agent affects MAN2A in a manner relevant to the IGFR pathway. In some cases, MAN2A modulators will be directly tested in a secondary assay.

[0060] In a preferred embodiment, the screening method comprises contacting a suitable assay system comprising a MAN2A polypeptide or nucleic acid with a candidate agent under conditions whereby, but for the presence of the agent, the system provides a reference activity (e.g. hydrolase activity), which is based on the particular molecular event the screening method detects. A statistically significant difference between the agent-biased activity and the reference activity indicates that the candidate agent

modulates MAN2A activity, and hence the IGFR pathway. The MAN2A polypeptide or nucleic acid used in the assay may comprise any of the nucleic acids or polypeptides described above.

Primary Assays

[0061] The type of modulator tested generally determines the type of primary assay.

Primary assays for small molecule modulators

[0062] For small molecule modulators, screening assays are used to identify candidate modulators. Screening assays may be cell-based or may use a cell-free system that recreates or retains the relevant biochemical reaction of the target protein (reviewed in Sittampalam GS *et al.*, Curr Opin Chem Biol (1997) 1:384-91 and accompanying references). As used herein the term "cell-based" refers to assays using live cells, dead cells, or a particular cellular fraction, such as a membrane, endoplasmic reticulum, or mitochondrial fraction. The term "cell free" encompasses assays using substantially purified protein (either endogenous or recombinantly produced), partially purified or crude cellular extracts. Screening assays may detect a variety of molecular events, including protein-DNA interactions, protein-protein interactions (*e.g.*, receptor-ligand binding), transcriptional activity (*e.g.*, using a reporter gene), enzymatic activity (*e.g.*, via a property of the substrate), activity of second messengers, immunogenicity and changes in cellular morphology or other cellular characteristics. Appropriate screening assays may use a wide range of detection methods including fluorescent, radioactive, colorimetric, spectrophotometric, and amperometric methods, to provide a read-out for the particular molecular event detected.

[0063] Cell-based screening assays usually require systems for recombinant expression of MAN2A and any auxiliary proteins demanded by the particular assay. Appropriate methods for generating recombinant proteins produce sufficient quantities of proteins that retain their relevant biological activities and are of sufficient purity to optimize activity and assure assay reproducibility. Yeast two-hybrid and variant screens, and mass spectrometry provide preferred methods for determining protein-protein interactions and elucidation of protein complexes. In certain applications, when MAN2A-interacting proteins are used in screens to identify small molecule modulators, the binding specificity of the interacting protein to the MAN2A protein may be assayed by various known methods such as substrate processing (*e.g.* ability of the candidate MAN2A-specific

binding agents to function as negative effectors in MAN2A-expressing cells), binding equilibrium constants (usually at least about 10^7 M^{-1} , preferably at least about 10^8 M^{-1} , more preferably at least about 10^9 M^{-1}), and immunogenicity (e.g. ability to elicit MAN2A specific antibody in a heterologous host such as a mouse, rat, goat or rabbit). For enzymes and receptors, binding may be assayed by, respectively, substrate and ligand processing.

[0064] The screening assay may measure a candidate agent's ability to specifically bind to or modulate activity of a MAN2A polypeptide, a fusion protein thereof, or to cells or membranes bearing the polypeptide or fusion protein. The MAN2A polypeptide can be full length or a fragment thereof that retains functional MAN2A activity. The MAN2A polypeptide may be fused to another polypeptide, such as a peptide tag for detection or anchoring, or to another tag. The MAN2A polypeptide is preferably human MAN2A, or is an ortholog or derivative thereof as described above. In a preferred embodiment, the screening assay detects candidate agent-based modulation of MAN2A interaction with a binding target, such as an endogenous or exogenous protein or other substrate that has MAN2A –specific binding activity, and can be used to assess normal MAN2A gene function.

[0065] Suitable assay formats that may be adapted to screen for MAN2A modulators are known in the art. Preferred screening assays are high throughput or ultra high throughput and thus provide automated, cost-effective means of screening compound libraries for lead compounds (Fernandes PB, *Curr Opin Chem Biol* (1998) 2:597-603; Sundberg SA, *Curr Opin Biotechnol* 2000, 11:47-53). In one preferred embodiment, screening assays uses fluorescence technologies, including fluorescence polarization, time-resolved fluorescence, and fluorescence resonance energy transfer. These systems offer means to monitor protein-protein or DNA-protein interactions in which the intensity of the signal emitted from dye-labeled molecules depends upon their interactions with partner molecules (*e.g.*, Selvin PR, *Nat Struct Biol* (2000) 7:730-4; Fernandes PB, *supra*; Hertzberg RP and Pope AJ, *Curr Opin Chem Biol* (2000) 4:445-451).

[0066] A variety of suitable assay systems may be used to identify candidate MAN2A and IGFR pathway modulators (*e.g.* U.S. Pat. Nos. 5,550,019 and 6,133,437 (apoptosis assays); and U.S. Pat. Nos. 5,976,782, 6,225,118 and 6,444,434 (angiogenesis assays), among others). Specific preferred assays are described in more detail below.

[0067] Hydrolase assays. Hydrolases catalyze the hydrolysis of a substrate such as esterases, lipases, peptidases, nucleotidases, and phosphatases, among others. Enzyme activity assays may be used to measure hydrolase activity. The activity of the enzyme is

determined in presence of excess substrate, by spectrophotometrically measuring the rate of appearance of reaction products. High throughput arrays and assays for hydrolases are known to those skilled in the art (Park CB and Clark DS (2002) *Biotech Bioeng* 78:229-235).

[0068] Apoptosis assays. Apoptosis or programmed cell death is a suicide program is activated within the cell, leading to fragmentation of DNA, shrinkage of the cytoplasm, membrane changes and cell death. Apoptosis is mediated by proteolytic enzymes of the caspase family. Many of the altering parameters of a cell are measurable during apoptosis. Assays for apoptosis may be performed by terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling (TUNEL) assay. The TUNEL assay is used to measure nuclear DNA fragmentation characteristic of apoptosis (Lazebnik *et al.*, 1994, *Nature* 371, 346), by following the incorporation of fluorescein-dUTP (Yonehara *et al.*, 1989, *J. Exp. Med.* 169, 1747). Apoptosis may further be assayed by acridine orange staining of tissue culture cells (Lucas, R., *et al.*, 1998, *Blood* 15:4730-41). Other cell-based apoptosis assays include the caspase-3/7 assay and the cell death nucleosome ELISA assay. The caspase 3/7 assay is based on the activation of the caspase cleavage activity as part of a cascade of events that occur during programmed cell death in many apoptotic pathways. In the caspase 3/7 assay (commercially available Apo-ONE™ Homogeneous Caspase-3/7 assay from Promega, cat# 67790), lysis buffer and caspase substrate are mixed and added to cells. The caspase substrate becomes fluorescent when cleaved by active caspase 3/7. The nucleosome ELISA assay is a general cell death assay known to those skilled in the art, and available commercially (Roche, Cat# 1774425). This assay is a quantitative sandwich-enzyme-immunoassay which uses monoclonal antibodies directed against DNA and histones respectively, thus specifically determining amount of mono- and oligonucleosomes in the cytoplasmic fraction of cell lysates. Mono and oligonucleosomes are enriched in the cytoplasm during apoptosis due to the fact that DNA fragmentation occurs several hours before the plasma membrane breaks down, allowing for accumulation in the cytoplasm. Nucleosomes are not present in the cytoplasmic fraction of cells that are not undergoing apoptosis. The Phospho-histone H2B assay is another apoptosis assay, based on phosphorylation of histone H2B as a result of apoptosis. Fluorescent dyes that are associated with phosphohistone H2B may be used to measure the increase of phosphohistone H2B as a result of apoptosis. Apoptosis assays that simultaneously measure multiple parameters associated with apoptosis have also been

developed. In such assays, various cellular parameters that can be associated with antibodies or fluorescent dyes, and that mark various stages of apoptosis are labeled, and the results are measured using instruments such as Cellomics™ ArrayScan® HCS System. The measurable parameters and their markers include anti-active caspase-3 antibody which marks intermediate stage apoptosis, anti-PARP-p85 antibody (cleaved PARP) which marks late stage apoptosis, Hoechst labels which label the nucleus and are used to measure nuclear swelling as a measure of early apoptosis and nuclear condensation as a measure of late apoptosis, TOTO-3 fluorescent dye which labels DNA of dead cells with high cell membrane permeability, and anti-alpha-tubulin or F-actin labels, which assess cytoskeletal changes in cells and correlate well with TOTO-3 label..

[0069] An apoptosis assay system may comprise a cell that expresses a MAN2A, and that optionally has defective IGFR function (e.g. IGFR is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the apoptosis assay system and changes in induction of apoptosis relative to controls where no test agent is added, identify candidate IGFR modulating agents. In some embodiments of the invention, an apoptosis assay may be used as a secondary assay to test a candidate IGFR modulating agents that is initially identified using a cell-free assay system. An apoptosis assay may also be used to test whether MAN2A function plays a direct role in apoptosis. For example, an apoptosis assay may be performed on cells that over- or under-express MAN2A relative to wild type cells. Differences in apoptotic response compared to wild type cells suggests that the MAN2A plays a direct role in the apoptotic response. Apoptosis assays are described further in US Pat. No. 6,133,437.

[0070] **Cell proliferation and cell cycle assays.** Cell proliferation may be assayed via bromodeoxyuridine (BRDU) incorporation. This assay identifies a cell population undergoing DNA synthesis by incorporation of BRDU into newly-synthesized DNA. Newly-synthesized DNA may then be detected using an anti-BRDU antibody (Hoshino *et al.*, 1986, Int. J. Cancer 38, 369; Campana *et al.*, 1988, J. Immunol. Meth. 107, 79), or by other means.

[0071] Cell proliferation is also assayed via phospho-histone H3 staining, which identifies a cell population undergoing mitosis by phosphorylation of histone H3. Phosphorylation of histone H3 at serine 10 is detected using an antibody specific to the phosphorylated form of the serine 10 residue of histone H3. (Chadlee, D.N. 1995, J. Biol. Chem 270:20098-105). Cell Proliferation may also be examined using [³H]-thymidine incorporation (Chen,

J., 1996, *Oncogene* 13:1395-403; Jeoung, J., 1995, *J. Biol. Chem.* 270:18367-73). This assay allows for quantitative characterization of S-phase DNA syntheses. In this assay, cells synthesizing DNA will incorporate [³H]-thymidine into newly synthesized DNA. Incorporation can then be measured by standard techniques such as by counting of radioisotope in a scintillation counter (e.g., Beckman LS 3800 Liquid Scintillation Counter). Another proliferation assay uses the dye Alamar Blue (available from Biosource International), which fluoresces when reduced in living cells and provides an indirect measurement of cell number (Voytik-Harbin SL et al., 1998, *In Vitro Cell Dev Biol Anim* 34:239-46). Yet another proliferation assay, the MTS assay, is based on in vitro cytotoxicity assessment of industrial chemicals, and uses the soluble tetrazolium salt, MTS. MTS assays are commercially available, for example, the Promega CellTiter 96[®] AQueous Non-Radioactive Cell Proliferation Assay (Cat.# G5421).

- [0072] Cell proliferation may also be assayed by colony formation in soft agar, or clonogenic survival assay (Sambrook et al., *Molecular Cloning*, Cold Spring Harbor (1989)). For example, cells transformed with MAN2A are seeded in soft agar plates, and colonies are measured and counted after two weeks incubation.
- [0073] Cell proliferation may also be assayed by measuring ATP levels as indicator of metabolically active cells. Such assays are commercially available, for example Cell Titer-Glo[™], which is a luminescent homogeneous assay available from Promega.
- [0074] Involvement of a gene in the cell cycle may be assayed by flow cytometry (Gray JW et al. (1986) *Int J Radiat Biol Relat Stud Phys Chem Med* 49:237-55). Cells transfected with a MAN2A may be stained with propidium iodide and evaluated in a flow cytometer (available from Becton Dickinson), which indicates accumulation of cells in different stages of the cell cycle.
- [0075] Involvement of a gene in cell cycle may also be assayed by FOXO nuclear translocation assays. The FOXO family of transcription factors are mediators of various cellular functions including cell cycle progression and cell death, and are negatively regulated by activation of the PI3 kinase pathway. Akt phosphorylation of FOXO family members leads to FOXO sequestration in the cytoplasm and transcriptional inactivation (Medema, R. H et al (2000) *Nature* 404: 782-787). PTEN is a negative regulator of PI3 kinase pathway. Activation of PTEN, or loss of PI3 kinase or AKT, prevents phosphorylation of FOXO, leading to accumulation of FOXO in the nucleus, transcriptional activation of FOXO regulated genes, and apoptosis. Alternatively, loss of PTEN leads to pathway activation and cell survival (Nakamura, N. et al (2000) *Mol Cell*

Biol 20: 8969-8982). FOXO translocation into the cytoplasm is used in assays and screens to identify members and/or modulators of the PTEN pathway. FOXO translocation assays using GFP or luciferase as detection reagents are known in the art (e.g., Zhang X et al (2002) J Biol Chem 277:45276-45284; and Li et al (2003) Mol Cell Biol 23:104-118).

[0076] Accordingly, a cell proliferation or cell cycle assay system may comprise a cell that expresses a MAN2A, and that optionally has defective IGFR function (e.g. IGFR is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the assay system and changes in cell proliferation or cell cycle relative to controls where no test agent is added, identify candidate IGFR modulating agents. In some embodiments of the invention, the cell proliferation or cell cycle assay may be used as a secondary assay to test a candidate IGFR modulating agents that is initially identified using another assay system such as a cell-free assay system. A cell proliferation assay may also be used to test whether MAN2A function plays a direct role in cell proliferation or cell cycle. For example, a cell proliferation or cell cycle assay may be performed on cells that over- or under-express MAN2A relative to wild type cells. Differences in proliferation or cell cycle compared to wild type cells suggests that the MAN2A plays a direct role in cell proliferation or cell cycle.

[0077] **Angiogenesis.** Angiogenesis may be assayed using various human endothelial cell systems, such as umbilical vein, coronary artery, or dermal cells. Suitable assays include Alamar Blue based assays (available from Biosource International) to measure proliferation; migration assays using fluorescent molecules, such as the use of Becton Dickinson Falcon HTS FluoroBlock cell culture inserts to measure migration of cells through membranes in presence or absence of angiogenesis enhancer or suppressors; and tubule formation assays based on the formation of tubular structures by endothelial cells on Matrigel® (Becton Dickinson). Accordingly, an angiogenesis assay system may comprise a cell that expresses a MAN2A, and that optionally has defective IGFR function (e.g. IGFR is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the angiogenesis assay system and changes in angiogenesis relative to controls where no test agent is added, identify candidate IGFR modulating agents. In some embodiments of the invention, the angiogenesis assay may be used as a secondary assay to test a candidate IGFR modulating agents that is initially identified using another assay system. An angiogenesis assay may also be used to test whether MAN2A function plays a direct role in cell proliferation. For example, an angiogenesis assay may be

performed on cells that over- or under-express MAN2A relative to wild type cells. Differences in angiogenesis compared to wild type cells suggests that the MAN2A plays a direct role in angiogenesis. U.S. Pat. Nos. 5,976,782, 6,225,118 and 6,444,434, among others, describe various angiogenesis assays.

[0078] Hypoxic induction. The alpha subunit of the transcription factor, hypoxia inducible factor-1 (HIF-1), is upregulated in tumor cells following exposure to hypoxia in vitro. Under hypoxic conditions, HIF-1 stimulates the expression of genes known to be important in tumour cell survival, such as those encoding glycolytic enzymes and VEGF. Induction of such genes by hypoxic conditions may be assayed by growing cells transfected with MAN2A in hypoxic conditions (such as with 0.1% O₂, 5% CO₂, and balance N₂, generated in a Napco 7001 incubator (Precision Scientific)) and normoxic conditions, followed by assessment of gene activity or expression by Taqman®. For example, a hypoxic induction assay system may comprise a cell that expresses a MAN2A, and that optionally has defective IGFR function (e.g. IGFR is over-expressed or under-expressed relative to wild-type cells). A test agent can be added to the hypoxic induction assay system and changes in hypoxic response relative to controls where no test agent is added, identify candidate IGFR modulating agents. In some embodiments of the invention, the hypoxic induction assay may be used as a secondary assay to test a candidate IGFR modulating agents that is initially identified using another assay system. A hypoxic induction assay may also be used to test whether MAN2A function plays a direct role in the hypoxic response. For example, a hypoxic induction assay may be performed on cells that over- or under-express MAN2A relative to wild type cells. Differences in hypoxic response compared to wild type cells suggests that the MAN2A plays a direct role in hypoxic induction.

[0079] Cell adhesion. Cell adhesion assays measure adhesion of cells to purified adhesion proteins, or adhesion of cells to each other, in presence or absence of candidate modulating agents. Cell-protein adhesion assays measure the ability of agents to modulate the adhesion of cells to purified proteins. For example, recombinant proteins are produced, diluted to 2.5g/mL in PBS, and used to coat the wells of a microtiter plate. The wells used for negative control are not coated. Coated wells are then washed, blocked with 1% BSA, and washed again. Compounds are diluted to 2× final test concentration and added to the blocked, coated wells. Cells are then added to the wells, and the unbound

cells are washed off. Retained cells are labeled directly on the plate by adding a membrane-permeable fluorescent dye, such as calcein-AM, and the signal is quantified in a fluorescent microplate reader.

[0080] Cell-cell adhesion assays measure the ability of agents to modulate binding of cell adhesion proteins with their native ligands. These assays use cells that naturally or recombinantly express the adhesion protein of choice. In an exemplary assay, cells expressing the cell adhesion protein are plated in wells of a multiwell plate. Cells expressing the ligand are labeled with a membrane-permeable fluorescent dye, such as BCECF, and allowed to adhere to the monolayers in the presence of candidate agents. Unbound cells are washed off, and bound cells are detected using a fluorescence plate reader.

[0081] High-throughput cell adhesion assays have also been described. In one such assay, small molecule ligands and peptides are bound to the surface of microscope slides using a microarray spotter, intact cells are then contacted with the slides, and unbound cells are washed off. In this assay, not only the binding specificity of the peptides and modulators against cell lines are determined, but also the functional cell signaling of attached cells using immunofluorescence techniques in situ on the microchip is measured (Falsey JR et al., *Bioconjug Chem.* 2001 May-Jun;12(3):346-53).

Primary assays for antibody modulators

[0082] For antibody modulators, appropriate primary assays test is a binding assay that tests the antibody's affinity to and specificity for the MAN2A protein. Methods for testing antibody affinity and specificity are well known in the art (Harlow and Lane, 1988, 1999, *supra*). The enzyme-linked immunosorbant assay (ELISA) is a preferred method for detecting MAN2A-specific antibodies; others include FACS assays, radioimmunoassays, and fluorescent assays.

[0083] In some cases, screening assays described for small molecule modulators may also be used to test antibody modulators.

Primary assays for nucleic acid modulators

[0084] For nucleic acid modulators, primary assays may test the ability of the nucleic acid modulator to inhibit or enhance MAN2A gene expression, preferably mRNA expression. In general, expression analysis comprises comparing MAN2A expression in like populations of cells (*e.g.*, two pools of cells that endogenously or recombinantly express

MAN2A) in the presence and absence of the nucleic acid modulator. Methods for analyzing mRNA and protein expression are well known in the art. For instance, Northern blotting, slot blotting, ribonuclease protection, quantitative RT-PCR (*e.g.*, using the TaqMan®, PE Applied Biosystems), or microarray analysis may be used to confirm that MAN2A mRNA expression is reduced in cells treated with the nucleic acid modulator (*e.g.*, Current Protocols in Molecular Biology (1994) Ausubel FM *et al.*, eds., John Wiley & Sons, Inc., chapter 4; Freeman WM *et al.*, Biotechniques (1999) 26:112-125; Kallioniemi OP, Ann Med 2001, 33:142-147; Blohm DH and Guiseppi-Elie, A Curr Opin Biotechnol 2001, 12:41-47). Protein expression may also be monitored. Proteins are most commonly detected with specific antibodies or antisera directed against either the MAN2A protein or specific peptides. A variety of means including Western blotting, ELISA, or in situ detection, are available (Harlow E and Lane D, 1988 and 1999, *supra*).

[0085] In some cases, screening assays described for small molecule modulators, particularly in assay systems that involve MAN2A mRNA expression, may also be used to test nucleic acid modulators.

Secondary Assays

[0086] Secondary assays may be used to further assess the activity of MAN2A-modulating agent identified by any of the above methods to confirm that the modulating agent affects MAN2A in a manner relevant to the IGFR pathway. As used herein, MAN2A-modulating agents encompass candidate clinical compounds or other agents derived from previously identified modulating agent. Secondary assays can also be used to test the activity of a modulating agent on a particular genetic or biochemical pathway or to test the specificity of the modulating agent's interaction with MAN2A.

[0087] Secondary assays generally compare like populations of cells or animals (*e.g.*, two pools of cells or animals that endogenously or recombinantly express MAN2A) in the presence and absence of the candidate modulator. In general, such assays test whether treatment of cells or animals with a candidate MAN2A-modulating agent results in changes in the IGFR pathway in comparison to untreated (or mock- or placebo-treated) cells or animals. Certain assays use “sensitized genetic backgrounds”, which, as used herein, describe cells or animals engineered for altered expression of genes in the IGFR or interacting pathways.

Cell-based assays

[0088] Cell based assays may detect endogenous IGFR pathway activity or may rely on recombinant expression of IGFR pathway components. Any of the aforementioned assays may be used in this cell-based format. Candidate modulators are typically added to the cell media but may also be injected into cells or delivered by any other efficacious means.

Animal Assays

[0089] A variety of non-human animal models of normal or defective IGFR pathway may be used to test candidate MAN2A modulators. Models for defective IGFR pathway typically use genetically modified animals that have been engineered to mis-express (*e.g.*, over-express or lack expression in) genes involved in the IGFR pathway. Assays generally require systemic delivery of the candidate modulators, such as by oral administration, injection, etc.

[0090] In a preferred embodiment, IGFR pathway activity is assessed by monitoring neovascularization and angiogenesis. Animal models with defective and normal IGFR are used to test the candidate modulator's affect on MAN2A in Matrigel® assays. Matrigel® is an extract of basement membrane proteins, and is composed primarily of laminin, collagen IV, and heparin sulfate proteoglycan. It is provided as a sterile liquid at 4° C, but rapidly forms a solid gel at 37° C. Liquid Matrigel® is mixed with various angiogenic agents, such as bFGF and VEGF, or with human tumor cells which over-express the MAN2A. The mixture is then injected subcutaneously(SC) into female athymic nude mice (Taconic, Germantown, NY) to support an intense vascular response. Mice with Matrigel® pellets may be dosed via oral (PO), intraperitoneal (IP), or intravenous (IV) routes with the candidate modulator. Mice are euthanized 5 - 12 days post-injection, and the Matrigel® pellet is harvested for hemoglobin analysis (Sigma plasma hemoglobin kit). Hemoglobin content of the gel is found to correlate the degree of neovascularization in the gel.

[0091] In another preferred embodiment, the effect of the candidate modulator on MAN2A is assessed via tumorigenicity assays. Tumor xenograft assays are known in the art (see, *e.g.*, Ogawa K et al., 2000, Oncogene 19:6043-6052). Xenografts are typically implanted SC into female athymic mice, 6-7 week old, as single cell suspensions either from a pre-existing tumor or from *in vitro* culture. The tumors which express the MAN2A endogenously are injected in the flank, 1×10^5 to 1×10^7 cells per mouse in a volume of 100 μ L using a 27gauge needle. Mice are then ear tagged and tumors are measured twice weekly. Candidate modulator treatment is initiated on the day the mean tumor weight

reaches 100 mg. Candidate modulator is delivered IV, SC, IP, or PO by bolus administration. Depending upon the pharmacokinetics of each unique candidate modulator, dosing can be performed multiple times per day. The tumor weight is assessed by measuring perpendicular diameters with a caliper and calculated by multiplying the measurements of diameters in two dimensions. At the end of the experiment, the excised tumors maybe utilized for biomarker identification or further analyses. For immunohistochemistry staining, xenograft tumors are fixed in 4% paraformaldehyde, 0.1M phosphate, pH 7.2, for 6 hours at 4°C, immersed in 30% sucrose in PBS, and rapidly frozen in isopentane cooled with liquid nitrogen.

[0092] In another preferred embodiment, tumorigenicity is monitored using a hollow fiber assay, which is described in U.S. Pat No. US 5,698,413. Briefly, the method comprises implanting into a laboratory animal a biocompatible, semi-permeable encapsulation device containing target cells, treating the laboratory animal with a candidate modulating agent, and evaluating the target cells for reaction to the candidate modulator. Implanted cells are generally human cells from a pre-existing tumor or a tumor cell line. After an appropriate period of time, generally around six days, the implanted samples are harvested for evaluation of the candidate modulator. Tumorigenicity and modulator efficacy may be evaluated by assaying the quantity of viable cells present in the macrocapsule, which can be determined by tests known in the art, for example, MTT dye conversion assay, neutral red dye uptake, trypan blue staining, viable cell counts, the number of colonies formed in soft agar, the capacity of the cells to recover and replicate in vitro, etc.

[0093] In another preferred embodiment, a tumorigenicity assay use a transgenic animal, usually a mouse, carrying a dominant oncogene or tumor suppressor gene knockout under the control of tissue specific regulatory sequences; these assays are generally referred to as transgenic tumor assays. In a preferred application, tumor development in the transgenic model is well characterized or is controlled. In an exemplary model, the "RIP1-Tag2" transgene, comprising the SV40 large T-antigen oncogene under control of the insulin gene regulatory regions is expressed in pancreatic beta cells and results in islet cell carcinomas (Hanahan D, 1985, Nature 315:115-122; Parangi S et al, 1996, Proc Natl Acad Sci USA 93: 2002-2007; Bergers G et al, 1999, Science 284:808-812). An "angiogenic switch," occurs at approximately five weeks, as normally quiescent capillaries in a subset of hyperproliferative islets become angiogenic. The RIP1-TAG2 mice die by age 14 weeks. Candidate modulators may be administered at a variety of stages, including just prior to the angiogenic switch (e.g., for a model of tumor prevention), during the growth of

small tumors (e.g., for a model of intervention), or during the growth of large and/or invasive tumors (e.g., for a model of regression). Tumorigenicity and modulator efficacy can be evaluating life-span extension and/or tumor characteristics, including number of tumors, tumor size, tumor morphology, vessel density, apoptotic index, etc.

Diagnostic and therapeutic uses

[0094] Specific MAN2A-modulating agents are useful in a variety of diagnostic and therapeutic applications where disease or disease prognosis is related to defects in the IGFR pathway, such as angiogenic, apoptotic, or cell proliferation disorders. Accordingly, the invention also provides methods for modulating the IGFR pathway in a cell, preferably a cell pre-determined to have defective or impaired IGFR function (e.g. due to overexpression, underexpression, or misexpression of IGFR, or due to gene mutations), comprising the step of administering an agent to the cell that specifically modulates MAN2A activity. Preferably, the modulating agent produces a detectable phenotypic change in the cell indicating that the IGFR function is restored. The phrase “function is restored”, and equivalents, as used herein, means that the desired phenotype is achieved, or is brought closer to normal compared to untreated cells. For example, with restored IGFR function, cell proliferation and/or progression through cell cycle may normalize, or be brought closer to normal relative to untreated cells. The invention also provides methods for treating disorders or disease associated with impaired IGFR function by administering a therapeutically effective amount of a MAN2A -modulating agent that modulates the IGFR pathway. The invention further provides methods for modulating MAN2A function in a cell, preferably a cell pre-determined to have defective or impaired MAN2A function, by administering a MAN2A -modulating agent. Additionally, the invention provides a method for treating disorders or disease associated with impaired MAN2A function by administering a therapeutically effective amount of a MAN2A -modulating agent.

[0095] The discovery that MAN2A is implicated in IGFR pathway provides for a variety of methods that can be employed for the diagnostic and prognostic evaluation of diseases and disorders involving defects in the IGFR pathway and for the identification of subjects having a predisposition to such diseases and disorders.

[0096] Various expression analysis methods can be used to diagnose whether MAN2A expression occurs in a particular sample, including Northern blotting, slot blotting, ribonuclease protection, quantitative RT-PCR, and microarray analysis. (e.g., Current

Protocols in Molecular Biology (1994) Ausubel FM *et al.*, eds., John Wiley & Sons, Inc., chapter 4; Freeman WM *et al.*, Biotechniques (1999) 26:112-125; Kallioniemi OP, Ann Med 2001, 33:142-147; Blohm and Guiseppi-Elie, Curr Opin Biotechnol 2001, 12:41-47). Tissues having a disease or disorder implicating defective IGFR signaling that express a MAN2A, are identified as amenable to treatment with a MAN2A modulating agent. In a preferred application, the IGFR defective tissue overexpresses a MAN2A relative to normal tissue. For example, a Northern blot analysis of mRNA from tumor and normal cell lines, or from tumor and matching normal tissue samples from the same patient, using full or partial MAN2A cDNA sequences as probes, can determine whether particular tumors express or overexpress MAN2A. Alternatively, the TaqMan® is used for quantitative RT-PCR analysis of MAN2A expression in cell lines, normal tissues and tumor samples (PE Applied Biosystems).

[0097] Various other diagnostic methods may be performed, for example, utilizing reagents such as the MAN2A oligonucleotides, and antibodies directed against a MAN2A, as described above for: (1) the detection of the presence of MAN2A gene mutations, or the detection of either over- or under-expression of MAN2A mRNA relative to the non-disorder state; (2) the detection of either an over- or an under-abundance of MAN2A gene product relative to the non-disorder state; and (3) the detection of perturbations or abnormalities in the signal transduction pathway mediated by MAN2A.

[0098] Kits for detecting expression of MAN2A in various samples, comprising at least one antibody specific to MAN2A, all reagents and/or devices suitable for the detection of antibodies, the immobilization of antibodies, and the like, and instructions for using such kits in diagnosis or therapy are also provided.

[0099] Thus, in a specific embodiment, the invention is drawn to a method for diagnosing a disease or disorder in a patient that is associated with alterations in MAN2A expression, the method comprising: a) obtaining a biological sample from the patient; b) contacting the sample with a probe for MAN2A expression; c) comparing results from step (b) with a control; and d) determining whether step (c) indicates a likelihood of the disease or disorder. Preferably, the disease is cancer, most preferably a cancer as shown in TABLE 1. The probe may be either DNA or protein, including an antibody.

EXAMPLES

[0100] The following experimental section and examples are offered by way of illustration and not by way of limitation.

I. Drosophila IGFR overexpression screen

[0101] A dominant loss of function screen was carried out in *Drosophila* to identify genes that interact with or modulate the IGFR signaling pathway. Activation of the pathway by overexpression of IGFR at early stages in the developing *Drosophila* eye leads to an increase in cell number which results in a larger and rougher adult eye (Potter CJ et al. (2001) Cell 105:357-368; Huang et al., 1999. Dev. 126:5365-5372). We generated a fly stock with an enlarged eye due to overexpression of IGFR and identified modifiers of this phenotype. We then identified human orthologues of these modifiers.

[0102] The screening stock carried two transgenes. The genotype is as follows:

[0103] +; +; P{DmIGFR-pExp-UAS} P{Gal4-pExp-1Xey}/TM6B

[0104] Screening stock females of the above genotype were crossed to males from a collection of 3 classes of piggyBac-based transposons. The resulting progeny, which contain both the transgenes and the transposon, were scored for the effect of the transposon on the eye overgrowth phenotype (either enhancement, suppression or no effect). All data was recorded and all modifiers were retested with a repeat of the original cross. Modifiers of the eye phenotype were identified as members of the IGFR pathway. CG4606 (Alpha-man-IIb) was a suppressor of the eye phenotype. Orthologs of the modifiers are referred to herein as MAN2A.

[0105] BLAST analysis (Altschul et al., *supra*) was employed to identify orthologs of *Drosophila* modifiers. For example, representative sequences from MAN2A, GI# 4758698 (SEQ ID NO:5), and GI#3123244 (SEQ ID NO:6) share 43% and 44% amino acid identity, respectively, with the *Drosophila* CG4606 (Alpha-man-IIb).

[0106] Various domains, signals, and functional subunits in proteins were analyzed using the PSORT (Nakai K., and Horton P., Trends Biochem Sci, 1999, 24:34-6; Kenta Nakai, Protein sorting signals and prediction of subcellular localization, Adv. Protein Chem. 54, 277-344 (2000)), PFAM (Bateman A., et al., Nucleic Acids Res, 1999, 27:260-2), SMART (Ponting CP, et al., SMART: identification and annotation of domains from signaling and extracellular protein sequences. Nucleic Acids Res. 1999 Jan 1;27(1):229-32), TM-HMM (Erik L.L. Sonnhammer, Gunnar von Heijne, and Anders Krogh: A hidden Markov model for predicting transmembrane helices in protein sequences. In Proc. of Sixth Int. Conf. on Intelligent Systems for Molecular Biology, p 175-182 Ed J. Glasgow, T. Littlejohn, F. Major, R. Lathrop, D. Sankoff, and C. Sensen Menlo Park, CA: AAAI Press, 1998), and clust (Remm M, and Sonnhammer E. Classification of transmembrane

protein families in the *Caenorhabditis elegans* genome and identification of human orthologs. *Genome Res.* 2000 Nov;10(11):1679-89) programs. For example, the Glycosyl hydrolases family 38 N-terminus domain (PFAM 01074) of MAN2A from GIs# 4758698 and 3123244 (SEQ ID NOs:5 and 6, respectively) is located respectively at approximately amino acid residues 167 to 498 and 167 to 498. Also, the Glycosyl hydrolases family 38 C-terminus domain (PFAM 07748) of MAN2A from GIs# 4758698 and 3123244 (SEQ ID NOs:5 and 6, respectively) is located respectively at approximately amino acid residues 648 to 1139 and 648 to 1135.

II. High-Throughput In Vitro Fluorescence Polarization Assay

[0107] Fluorescently-labeled MAN2A peptide/substrate are added to each well of a 96-well microtiter plate, along with a test agent in a test buffer (10 mM HEPES, 10 mM NaCl, 6 mM magnesium chloride, pH 7.6). Changes in fluorescence polarization, determined by using a Fluorolite FPM-2 Fluorescence Polarization Microtiter System (Dynatech Laboratories, Inc), relative to control values indicates the test compound is a candidate modifier of MAN2A activity.

III. High-Throughput In Vitro Binding Assay.

[0108] ³³P-labeled MAN2A peptide is added in an assay buffer (100 mM KCl, 20 mM HEPES pH 7.6, 1 mM MgCl₂, 1% glycerol, 0.5% NP-40, 50 mM beta-mercaptoethanol, 1 mg/ml BSA, cocktail of protease inhibitors) along with a test agent to the wells of a Neutralite-avidin coated assay plate and incubated at 25°C for 1 hour. Biotinylated substrate is then added to each well and incubated for 1 hour. Reactions are stopped by washing with PBS, and counted in a scintillation counter. Test agents that cause a difference in activity relative to control without test agent are identified as candidate IGFR modulating agents.

IV. Immunoprecipitations and Immunoblotting

[0109] For coprecipitation of transfected proteins, 3×10^6 appropriate recombinant cells containing the MAN2A proteins are plated on 10-cm dishes and transfected on the following day with expression constructs. The total amount of DNA is kept constant in each transfection by adding empty vector. After 24 h, cells are collected, washed once with phosphate-buffered saline and lysed for 20 min on ice in 1 ml of lysis buffer containing 50 mM Hepes, pH 7.9, 250 mM NaCl, 20 mM -glycerophosphate, 1 mM

sodium orthovanadate, 5 mM p-nitrophenyl phosphate, 2 mM dithiothreitol, protease inhibitors (complete, Roche Molecular Biochemicals), and 1% Nonidet P-40. Cellular debris is removed by centrifugation twice at $15,000 \times g$ for 15 min. The cell lysate is incubated with 25 μ l of M2 beads (Sigma) for 2 h at 4 °C with gentle rocking.

[0110] After extensive washing with lysis buffer, proteins bound to the beads are solubilized by boiling in SDS sample buffer, fractionated by SDS-polyacrylamide gel electrophoresis, transferred to polyvinylidene difluoride membrane and blotted with the indicated antibodies. The reactive bands are visualized with horseradish peroxidase coupled to the appropriate secondary antibodies and the enhanced chemiluminescence (ECL) Western blotting detection system (Amersham Pharmacia Biotech).

V. Expression analysis

[0111] All cell lines used in the following experiments are NCI (National Cancer Institute) lines, and are available from ATCC (American Type Culture Collection, Manassas, VA 20110-2209). Normal and tumor tissues were obtained from Impath, UC Davis, Clontech, Stratagene, Ardaïs, Genome Collaborative, and Ambion.

[0112] TaqMan® analysis was used to assess expression levels of the disclosed genes in various samples.

[0113] RNA was extracted from each tissue sample using Qiagen (Valencia, CA) RNeasy kits, following manufacturer's protocols, to a final concentration of 50ng/ μ l. Single stranded cDNA was then synthesized by reverse transcribing the RNA samples using random hexamers and 500ng of total RNA per reaction, following protocol 4304965 of Applied Biosystems (Foster City, CA).

[0114] Primers for expression analysis using TaqMan® assay (Applied Biosystems, Foster City, CA) were prepared according to the TaqMan® protocols, and the following criteria: a) primer pairs were designed to span introns to eliminate genomic contamination, and b) each primer pair produced only one product. Expression analysis was performed using a 7900HT instrument.

[0115] TaqMan® reactions were carried out following manufacturer's protocols, in 25 μ l total volume for 96-well plates and 10 μ l total volume for 384-well plates, using 300nM primer and 250 nM probe, and approximately 25ng of cDNA. The standard curve for result analysis was prepared using a universal pool of human cDNA samples, which is a mixture of cDNAs from a wide variety of tissues so that the chance that a target will be

present in appreciable amounts is good. The raw data were normalized using 18S rRNA (universally expressed in all tissues and cells).

[0116] For each expression analysis, tumor tissue samples were compared with matched normal tissues from the same patient. A gene was considered overexpressed in a tumor when the level of expression of the gene was 2 fold or higher in the tumor compared with its matched normal sample. In cases where normal tissue was not available, a universal pool of cDNA samples was used instead. In these cases, a gene was considered overexpressed in a tumor sample when the difference of expression levels between a tumor sample and the average of all normal samples from the same tissue type was greater than 2 times the standard deviation of all normal samples (i.e., $\text{Tumor} - \text{average}(\text{all normal samples}) > 2 \times \text{STDEV}(\text{all normal samples})$).

[0117] Results are shown in Table 1. Number of pairs of tumor samples and matched normal tissue from the same patient are shown for each tumor type. Percentage of the samples with at least two-fold overexpression for each tumor type is provided. A modulator identified by an assay described herein can be further validated for therapeutic effect by administration to a tumor in which the gene is overexpressed. A decrease in tumor growth confirms therapeutic utility of the modulator. Prior to treating a patient with the modulator, the likelihood that the patient will respond to treatment can be diagnosed by obtaining a tumor sample from the patient, and assaying for expression of the gene targeted by the modulator. The expression data for the gene(s) can also be used as a diagnostic marker for disease progression. The assay can be performed by expression analysis as described above, by antibody directed to the gene target, or by any other available detection method.

Table1

Gene Name	MAN2A1 (SEQ ID NO:1)	MAN2A2 (SEQ ID NO:4)
Breast	17%	8%
# of Pairs	36	36
Colon	12%	8%
# of Pairs	40	40
Head And Neck	8%	0%
# of Pairs	13	13
Liver	11%	22%
# of Pairs	9	9
Lung	10%	2%

# of Pairs	40	40
Lymphoma	0%	0%
# of Pairs	4	4
Ovary	5%	21%
# of Pairs	19	19
Pancreas	42%	33%
# of Pairs	12	12
Prostate	8%	8%
# of Pairs	24	24
Skin	0%	43%
# of Pairs	7	7
Stomach	0%	9%
# of Pairs	11	11
Testis	0%	0%
# of Pairs	8	8
Thyroid Gland	14%	7%
# of Pairs	14	14
Uterus	17%	9%
# of Pairs	23	23

VI. MAN2A functional assays

[0118] RNAi experiments were carried out to knock down expression of MAN2A1 and MAN2A2 (SEQ ID NOs:1 and 4, respectively) in various cell lines using small interfering RNAs (siRNA, Elbashir et al, *supra*).

[0119] Effect of MAN2A RNAi on cell proliferation and growth. BrdU and Cell Titer-Glo™ assays, as described above, were employed to study the effects of decreased MAN2A expression on cell proliferation. The results of these experiments indicated that RNAi of both MAN2A1 and MAN2A2 (SEQ ID Nos:1 and 4) decreased proliferation in 231T breast cancer cells, A549 lung cancer cells, PC3 prostate cancer cells, and U87MG glioblastoma cells.

[0120] Standard colony growth assays, as described above, were employed to study the effects of decreased MAN2A expression on cell growth. The results of this experiment indicated that RNAi of MAN2A1 (SEQ ID NO:1) decreased proliferation in A549 cells and A2780 ovarian cancer cells, while causing decreased cell count in 231T, PC3, and A549 cells. RNAi of MAN2A2 (SEQ ID NO:4) caused decreased cell count in A549 cells.

[0121] [³H]-thymidine incorporation assay, as described above, was also employed to study the effects of decreased MAN2A expression on cell proliferation. The results of this experiment indicated that RNAi of MAN2A of SEQ ID NO:1 decreased proliferation in

A549 and A2780 cells, and also in RD1 rhabdomyosarcoma cells. RNAi of MAN2A of SEQ ID NO:4 decreased proliferation in A549 and RD1 cells.

[0122] Effect of MAN2A RNAi on apoptosis. The Phospho-histone H2B assay, as described above, was employed to study the effects of decreased MAN2A expression on apoptosis. The results of this experiment indicated that RNAi of MAN2A of SEQ ID NO:1 increased apoptosis in 231T, PC3, and U87MG cells; and RNAi of MAN2A of SEQ ID NO:4 increased apoptosis in PC3 cells.

[0123] Multiple parameter apoptosis assay, as described above, was also used to study the effects of decreased MAN2A expression on apoptosis. The results of this experiment indicated that RNAi of each MAN2A1 and MAN2A2 (SEQ ID Nos:1 and 4) increased apoptosis in A2780 and A549 cells.

[0124] Transcriptional reporter assays. Effects of overexpressed MAN2A on expression of various transcription factors was also studied. Overexpressed MAN2A caused an increased expression of the following transcription factors: ??????. Additionally, other transcriptional reporter assay was also performed to measure the effects of overexpressed MAN2A on expression of various transcription factors. In this assay, rat intestinal epithelial cells (RIEs) or NIH3T3 cells were co-transfected with reporter constructs containing various transcription factors and luciferase along with MAN2A. Luciferase intensity was then measured as the readout for transcriptional activation due to overexpression of the MAN2A. Overexpressed MAN2A of SEQ ID NO:1 caused an increased expression of AP1 (Activator protein 1) transcription factor.

[0125] Involvement in PTEN/IGF pathway: MAN2A FOXO nuclear translocation assays. FOXO nuclear translocation assays, as described above, were employed to assess involvement of MAN2A in the PTEN/IGF pathway. In one set of experiments, cells with reduced expression of MAN2A by RNAi were transiently transfected with a plasmid expressing GFP-tagged FOXO. Automated imaging of cellular components, such as nucleus and cytoplasm were then carried out to assess translocation of FOXO. Results indicated that reduced expression of MAN2A of SEQ ID NO:1 led to retention of FOXO in the nucleus, translocation of FOXO to the cytoplasm, similar to loss of PTEN, in U2OS osteosarcoma cells. In another set of experiments, cells were co-transfected with siRNA directed to MAN2A along with a plasmid containing FOXO, and a cassette containing a promoter, a FOXO response element, and luciferase. Cells were then analyzed for luciferase activity and compared with cells with no siRNA. Results indicated that reduced expression of MAN2A1 (SEQ ID NO:1) led to translocation of FOXO to the cytoplasm in

A2780 and PC3 cells, and reduced expression of MAN2A2 (SEQ ID NO:4) led to translocation of FOXO to the cytoplasm in A2780 cells. These results suggest involvement of MAN2A in the PTEN/IGFR pathway.

[0126] Pan-AKT assays. This assay was developed to detect involvement of MAN2A in the PTEN/IGFR pathway. The assay detects changes in phosphorylation for several substrates of AKT, such as PRAS40, BAD, 4EBP1, and RPS6. For this experiment, antibodies were raised against phosphorylated AKT substrates, including the consensus phosphorylated AKT substrate sequence RxRxxS/T. Expression levels of phosphorylated substrates were then quantitated at normal levels, in presence of a negative control, a positive control (AKT), and then with MAN2A knockout. For example, when AKT levels were reduced, expression of all its substrates was also reduced. Results indicated that RNAi of MAN2A1 and MAN2A2 (SEQ ID NOs:1 and 4, respectively), reduced the level of phosphorylated AKT substrates in 231T and A549 cells.

[0127] We used RPS6 as a substrate for one subset of experiments. RPS6 is an IGF dependent substrate of AKT. IGF1 treatment increases cytoplasmic RPS6 levels. Alternatively, Lily compound LY294002, a PI3K inhibitor, reduces AKT and cytoplasmic RPS6 levels. Cells were plated in 96 well plates, transfected with RNAi for MAN2A, fixed, treated with RPS6 antibody, and stained. Measurements were based on percentage of population of cells with increased or decreased staining compared with negative or positive control cells. Results of this experiment showed that RNAi of MAN2A1 (SEQ ID NO:1) caused a reduction in the amount of phosphorylated RPS6 in A549 cells.

[0128] We used 4EBP1 as the substrate in another subset of experiments. For this substrate, AKT pathway inhibition causes decreased cytoplasmic staining and increased nuclear staining. Cells were plated in 96 well plates, transfected with RNAi for MAN2A, fixed, treated with 4EBP1 antibody, and stained. Measurements were based on percentage of population of cells with increased or decreased nuclear/cytoplasmic staining ratio compared with negative or positive control cells. Results of this experiment showed that RNAi of MAN2A1 (SEQ ID NO:1) caused a reduction in the amount of phosphorylated 4EBP1 in A549 cells.

[0129] We also used PRAS40 as the substrate another subset of experiments. For this substrate, pathway inhibition causes decreased cytoplasmic staining and increased nuclear and perinuclear staining. Cells were plated in 96 well plates, transfected with RNAi for MAN2A, fixed, treated with PRAS40 antibody, and stained. Measurements were based on percentage of population of cells with increased or decreased nuclear/cytoplasmic

staining ratio compared with negative or positive control cells. Results of this experiment showed that RNAi of MAN2A1 (SEQ ID NO:1) caused a reduction in the amount of phosphorylated PRAS40 in 231T, PC3, and A549 cells; and RNAi of MAN2A2 (SEQ ID NO:4) caused a reduction in the amount of phosphorylated PRAS40 in A549 cells.. Taken together, these results suggest involvement of MAN2A in the IGFR pathway.

[0130] High Throughput PTEN/IGF Transcriptional readout assay. This assay is an expanded TaqMan® transcriptional readout assay monitoring changes in the mRNA levels of endogenous PTEN/IGF regulated genes. This assay measures changes in expression of PTEN/IGF regulated cellular genes as a readout for pathway signaling activity.

[0131] We identified a panel of genes that were transcriptionally regulated by PTEN/IGF signaling, then designed and tested TaqMan® primer/probes sets. We reduced expression of PTEN/IGF by RNAi, and tested its affect on the expression of the transcriptionally regulated genes in multiple cell types. The panel readout was then narrowed to the ten most robust probes.

[0132] We then treated cancer cells with siRNAs of the target genes of interest, such as MAN2A, and tested how the reduced levels of the target genes affected the expression levels of the PTEN/IGF regulated gene panel.

[0133] Genes that when knocked out via at least 2 different RNAi oligos, demonstrated the same pattern of activity on at least one third of the panel genes as a PTEN/IGF knockout, were identified as involved in the PTEN/IGF pathway.

[0134] TaqMan® assays were performed on the RNAs in a 384 well format.

[0135] RNAi of MAN2A1 (SEQ ID NO:1) showed the same pattern of activity as PTEN/IGF RNAi for at least 2 RNAi oligos on at least one third of the transcriptionally regulated genes in 231T and PC3 cells.

WHAT IS CLAIMED IS:

1. A method of identifying a candidate IGFR pathway modulating agent, said method comprising the steps of:
 - (a) providing an assay system comprising a MAN2A polypeptide or nucleic acid;
 - (b) contacting the assay system with a test agent under conditions whereby, but for the presence of the test agent, the system provides a reference activity; and
 - (c) detecting a test agent-biased activity of the assay system, wherein a difference between the test agent-biased activity and the reference activity identifies the test agent as a candidate IGFR pathway modulating agent.
2. The method of Claim 1 wherein the assay system comprises cultured cells that express the MAN2A polypeptide.
3. The method of Claim 2 wherein the cultured cells additionally have defective IGFR function.
4. The method of Claim 1 wherein the assay system includes a screening assay comprising a MAN2A polypeptide, and the candidate test agent is a small molecule modulator.
5. The method of Claim 4 wherein the assay is a hydrolase assay.
6. The method of Claim 1 wherein the assay system is selected from the group consisting of an apoptosis assay system, a cell proliferation assay system, an angiogenesis assay system, and a hypoxic induction assay system.
7. The method of Claim 1 wherein the assay system includes a binding assay comprising a MAN2A polypeptide and the candidate test agent is an antibody.

8. The method of Claim 1 wherein the assay system includes an expression assay comprising a MAN2A nucleic acid and the candidate test agent is a nucleic acid modulator.

9. The method of claim 8 wherein the nucleic acid modulator is an antisense oligomer.

10. The method of Claim 8 wherein the nucleic acid modulator is a PMO.

11. The method of Claim 1 additionally comprising:

(d) administering the candidate IGFR pathway modulating agent identified in (c) to a model system comprising cells defective in IGFR function and, detecting a phenotypic change in the model system that indicates that the IGFR function is restored.

12. The method of Claim 11 wherein the model system is a mouse model with defective IGFR function.

13. A method for modulating an IGFR pathway of a cell comprising contacting a cell defective in IGFR function with a candidate modulator that specifically binds to a MAN2A polypeptide, whereby IGFR function is restored.

14. The method of claim 13 wherein the candidate modulator is administered to a vertebrate animal predetermined to have a disease or disorder resulting from a defect in IGFR function.

15. The method of Claim 13 wherein the candidate modulator is selected from the group consisting of an antibody and a small molecule.

16. The method of Claim 1, comprising the additional steps of:

(d) providing a secondary assay system comprising cultured cells or a non-human animal expressing MAN2A ,

(e) contacting the secondary assay system with the test agent of (b) or an agent derived therefrom under conditions whereby, but for the presence of the test agent or agent derived therefrom, the system provides a reference activity; and

(f) detecting an agent-biased activity of the second assay system,
wherein a difference between the agent-biased activity and the reference activity of the second assay system confirms the test agent or agent derived therefrom as a candidate IGFR pathway modulating agent,
and wherein the second assay detects an agent-biased change in the IGFR pathway.

17. The method of Claim 16 wherein the secondary assay system comprises cultured cells.

18. The method of Claim 16 wherein the secondary assay system comprises a non-human animal.

19. The method of Claim 18 wherein the non-human animal mis-expresses an IGFR pathway gene.

20. A method of modulating IGFR pathway in a mammalian cell comprising contacting the cell with an agent that specifically binds a MAN2A polypeptide or nucleic acid.

21. The method of Claim 20 wherein the agent is administered to a mammalian animal predetermined to have a pathology associated with the IGFR pathway.

22. The method of Claim 20 wherein the agent is a small molecule modulator, a nucleic acid modulator, or an antibody.

23. A method for diagnosing a disease in a patient comprising:
obtaining a biological sample from the patient;
contacting the sample with a probe for MAN2A expression;
comparing results from step (b) with a control;
determining whether step (c) indicates a likelihood of disease.

24. The method of claim 23 wherein said disease is cancer.

25. The method according to claim 24, wherein said cancer is a cancer as shown in Table 1 as having >25% expression level.

EX05-005patentin.txt
SEQUENCE LISTING

<110> EXELIXIS, INC.

<120> MAN2AS AS MODIFIERS OF THE IGFR PATHWAY AND METHODS OF USE

<130> EX05-005

<150> US60/539,837

<151> 2004-01-28

<160> 6

<170> PatentIn version 3.2

<210> 1

<211> 4101

<212> DNA

<213> Homo sapiens

<400> 1

```

ggctcctcgc gatcttggtc ctttcccctc cgcttctctg acctagctgc gcggccccgg      60
cccgggagct gccgaacccg cgcctcccct ggggtgaggag gacacgcctg ccctcgtcga      120
gaaaactttt cctgccgact cagttggggc ggcggtggca ggaagtgcgg gcagcgacct      180
ctcctccgcc tgccccgcgc gccctgccgg aggtcggcgc tgagcttgcg atcaagtttg      240
tggggggccc ctttcccagt tgccggcgag tctcgcctcg agaggggagc ccgacccccg      300
ggagggcggc aggccagggc gaaggccaag ggcgttttgt ggcgccggag actaggtgcg      360
gagcaaggcg gggactcgca ccgcacccg agagcgcgga ggtcgcgcag cccgggagaa      420
gggagcctcc ggcggctgct tcctagagtc cacagtgcgc tgtctccttt ggctgaggag      480
agtgtcctgg ccccgagtct atcgaggaaa atgaagttaa gccgccagtt caccgtgttc      540
ggcagtgcga tcttctgtgt ggtgattttc tcgctctacc tgatgctgga ccggggtcac      600
ttagactacc ccaggaaccc gcgccgcgag ggctccttcc ctgaggcca gctctcaatg      660
ttgcaagaaa aaatagacca tttggagcgt ttgctagctg agaataatga gatcatctca      720
aatattagag actcagtcac caatttgagt gagtctgtgg aggatgggtc gaaaagttca      780
caaagcaatt tcagccaagg tgctggctca catcttctgc cctcacaatt atccctctca      840
gttgacactg cagactgtct gtttgcttca caaagtggaa gtcacaattc agatgtgcag      900
atgttggatg ttacagtcct aatttctttt gacaatccag atggtggagt ttggaagcaa      960
ggatttgaca ttacttatga atctaataa tgggacactg aacccttca agtctttgtg      1020
gtgcctcatt ccataacga ccaggttggt ttgaagactt tcaatgacta ctttagagac      1080
aagactcagt atatttttta taacatggtc ctaaagctga aagaagactc acggaggaag      1140
tttatttggt ctgagatctc ttacctttca aagtgggtgg atattataga tattcagaag      1200
aaggatgctg ttaaaagtgt aatagaaaat ggtcagcttg aaattgtgac aggtggctgg      1260
gttatgcctg atgaagctac tccacattat tttgccttaa ttgatcaact aattgaagga      1320
catcagtggc tggaaaataa tataggagtg aaacctcggt ccggctgggc tattgatccc      1380
tttggacact caccaacaat ggcttatctt ctaaaccgtg ctggactttc tcacatgctt      1440

```

EX05-005patentin.txt

atccagagag	ttcattatgc	agttaaaaaa	cactttgcac	tgcataaaac	attggagttt	1500
ttttggagac	agaattggga	tctgggatct	gtcacagata	ttttatgcca	catgatgccc	1560
ttctacagct	atgacatccc	tcacacttgt	ggacctgac	ctaaaatatg	ctgccagttt	1620
gatttttaaac	gtcttcctgg	aggcagat	ggttgtccct	ggggaggtccc	cccagaaaca	1680
atacatcctg	gaaatgtcca	aagcagggct	cggatgctac	tagatcagta	ccgaaagaag	1740
tcaaagcttt	ttcgtacca	agttctcctg	gctccactag	gagatgattt	ccgctactgt	1800
gaatacacgg	aattgggattt	acagtttaag	aattatcagc	agctttttga	ttatatgaat	1860
tctcagtgcca	agtttaaaagt	taagatacag	tttggaaactt	tatcagattt	ttttgatgcg	1920
ctggataaag	cagatgaaac	tcagagagac	aagggccagt	cgatgttccc	tgttttaagt	1980
ggagatTTTT	tcacttatgc	cgatcgagat	gatcattact	ggagtggcta	ttttacatcc	2040
agaccctttt	acaaacgaat	ggacagaatc	atggaatctc	atttaagggc	tgctgaaatt	2100
ctttactatt	tcgccctgag	acaagctcac	aaatacaaga	taaataaatt	tctctcatca	2160
tcactttaca	cggcactgac	agaagccaga	aggaatttgg	gactgtttca	acatcatgat	2220
gctatcacag	gaactgcaaa	agactgggtg	gttgtggatt	atggtaccag	actttttcat	2280
tcgttaaatgg	ttttggagaa	gataattgga	aattctgcat	ttcttcttat	tttgaaggac	2340
aaactcacat	acgactctta	ctctcctgat	accttcctgg	agatggattt	gaaacaaaaa	2400
tcacaagatt	ctctgccaca	aaaaaatata	ataaggctga	gtgcgagacc	aaggtacctt	2460
gtggtctata	atcctttaga	acaagaccga	atctcgttgg	tctcagtcta	tgtgagttcc	2520
ccgacagtgc	aagtgttctc	tgcttcagga	aaacctgtgg	aagttcaagt	cagcgcagtt	2580
tgggatacag	caaatactat	ttcagaaaca	gcctatgaga	tctcttttcg	agcacatata	2640
ccgccattgg	gactgaaagt	gtataagatt	ttggaatcag	caagttcaaa	ttcacattta	2700
gctgattatg	tcttgtataa	gaataaagta	gaagatagcg	gaattttcac	cataaagaat	2760
atgataaata	ctgaagaagg	tataacacta	gagaactcct	ttgttttact	tcggtttgat	2820
caaactggac	ttatgaagca	aatgatgact	aaagaagatg	gtaaacacca	tgaagtaaat	2880
gtgcaatttt	catggtatgg	aaccacaatt	aaaagagaca	aaagtgggtg	ctacctcttc	2940
ttacctgatg	gtaatgccaa	gccttatgtt	tacacaacac	cgccctttgt	cagagtgaca	3000
catggaagga	tttattcgga	agtgacttgc	ttttttgacc	atgttactca	tagagtccga	3060
ctataccaca	tacaggggaat	agaaggacag	tctgtggaag	tttccaatat	tgtggacatc	3120
cgaagagtat	ataaccgtga	gattgcaatg	aaaatttctt	ctgatataaa	aagccaaaat	3180
agattttata	ctgacctaaa	tgggtaccag	attcaaccta	gaatgacact	gagcaaatg	3240
cctcttcaag	caaatgtcta	tcccatgacc	acaatggcct	atatccagga	tgccaaacat	3300
cgtttgacac	tgctctctgc	tcagtcttta	ggggtttcga	gtttgaatag	tggtcagatt	3360
gaagttatca	tggatcgaag	actcatgcaa	gatgataatc	gtggccttga	gcaaggtatc	3420
caggataaca	agattacagc	taatctat	cgaatactac	tagaaaaaag	aagtgtgttt	3480

EX05-005patentin.txt

```

aatacgggaag aagaaaagaa gtcggtcagt tatccttctc tccttagcca cataacttct 3540
tctctcatga atcatccagt cattccaatg gcaaataagt tctcacctac ccttgagctg 3600
caagggtgaat tctctccatt acagtcattt ttgccttggtg acattcatct ggtaatttg 3660
agaacaatac agtcaaagggt gggcaatggg cactccaatg aggcagcctt gatcctccac 3720
agaaaagggt ttgattgtcg gttctctagc aaaggcacag ggctgttttg ttctactact 3780
cagggaaga tattggtaca gaaactttta aacaagttaa ttgtcgaaag tctcacacct 3840
tcatcactat ccttgatgca ttcacctccc ggcactcaga atataagtga gatcaacttg 3900
agtccaatgg aaatcagcac attccgaatc cagttgaggt gaacctgact ttcacatttg 3960
gattgagaat cattggcttt tatacctttc ttggtttgac gtgcaataaa gaagcacatt 4020
atcttagctt ctggctactg tgagaacatg aattctgtga ttctgtgggt ttttctttt 4080
ttcttttacc agtacagtaa g 4101

```

```

<210> 2
<211> 3599
<212> DNA
<213> Homo sapiens

```

```

<400> 2
aaaatgaagt taagccgcca gttcaccgtg ttcggcagtg cgatcttctg tgtggtgatt 60
ttctcgctct acctgatgct ggaccgggggt cacttagact accccaggaa cccgcgccgc 120
gagggctcct tccctcaggg ccagctctca atgttgcaag aaaaaataga ccatttgag 180
cgtttgctag ctgagaataa tgagatcatc tcaaatatta gagactcagt catcaatttg 240
agtgagtctg tggaggatgg tccgaaaagt tcacaaagca atttcagcca aggtgctggc 300
tcacatcttc tgccctcaca attatccctc tcagttgaca ctgcagactg tctgtttgct 360
tcacaaagtg gaagtcacaa ttcagatgtg cagatgttg atgtttacag tctaatttct 420
tttgacaatc cagatggtgg agtttggaag caaggatttg acattactta tgaatctaata 480
gaatgggaca ctgaaccctt tcaagtcttt gtggtgcctc attcccataa cgaccaggt 540
tggttgaaga ctttcaatga ctactttaga gacaagactc agtatatttt taataacatg 600
gtcctaaagc tgaaagaaga ctcacggagg aagtttattt ggtctgagat ctcttacctt 660
tcaaagtggg gggatattat agatattcag aagaaggatg ctgttaaaag tttaatagaa 720
aatggctcagc ttgaaattgt gacagggtggc tgggttatgc ctgatgaagc tactccacat 780
tattttgcct taattgatca actaattgaa ggacatcagt ggctggaaaa taatatagga 840
gtgaaacctc ggtccggctg ggctattgat ccttttgac actcaccaac aatggcttat 900
cttctaaacc gtgctggact ttctcacatg cttatccaga gagttcatta tgcagttaaa 960
aaacactttg cactgcataa aacattggag tttttttgga gacagaattg ggatctggga 1020
tctgtcacag atattttatg ccacatgatg ccttctaca gctatgacat ccctcacact 1080
tgtggacctg atcctaaaat atgctgccag tttgatttta aacgtcttcc tggaggcaga 1140

```

EX05-005patentin.txt

tttggttgct	cctggggagt	ccccccagaa	acaatacatc	ctggaaatgt	ccaaagcagg	1200
gctcggatgc	tactagatca	gtaccgaaag	aagtcaaagc	tttttcgaac	caaagttctc	1260
ctggctccac	taggagatga	tttccgctac	tgtgaataca	cggaatggga	tttacagttt	1320
aagaattatc	agcagctttt	tgattatatg	aattctcagt	ccaagtttaa	agttaagata	1380
cagtttgga	ctttatcaga	tttttttgat	gcgctggata	aagcagatga	aactcagaga	1440
gacaagggcc	aatcgatgtt	ccctgtttta	agtggagatt	ttttcactta	tgccgatcga	1500
gatgatcatt	actggagtgg	ctatttttaca	tccagaccct	tttacaaacg	aatggacaga	1560
atcatggaat	ctcatttaag	ggctgctgaa	attctttact	atttcgccct	gagacaagct	1620
cacaaatata	agataaataa	atttctctca	tcataccttt	acacggcact	gacagaagcc	1680
agaaggaatt	tgggactgtt	tcaacatcat	gatgctatca	caggaactgc	aaaagactgg	1740
gtggttggtg	attatggtac	cagacttttt	cattcgtaa	tggttttgga	gaagataatt	1800
ggaaattctg	catttcttct	tattgggaag	gacaaactca	catacgactc	ttactctcct	1860
gataccttcc	tggagatgga	tttgaaacaa	aatcacaaag	attctctgcc	acaaaaaaaaat	1920
ataataaggc	tgagtgcgga	gccaaaggta	cttggtgtct	ataatccttt	agaacaagac	1980
cgaatctcgt	tggctctcagt	ctatgtgagt	tccccgacag	tgcaagtgtt	ctctgcttca	2040
ggaaaacctg	tggaagtcca	agtcagcgca	gtttgggata	cagcaaatac	tatttcagaa	2100
acagcctatg	agatctcttt	tcgagcacat	ataccgccat	tgggactgaa	agtgtataag	2160
attttggaat	cagcaagttc	aaattcacat	ttagctgatt	atgtcttgta	taagaataaaa	2220
gtagaagata	gcggaatttt	caccataaag	aatatgataa	atactgaaga	aggtataaca	2280
ctagagaact	cctttgtttt	acttcggttt	gatcaaactg	gacttatgaa	gcaaatgatg	2340
actaaagaag	atggtaaaca	ccatgaagta	aatgtgcaat	tttcatggta	tggaaccaca	2400
attaaaagag	acaaaagtgg	tgcttacctc	ttcttacctg	atggtaatgc	caagccttat	2460
gtttacacaa	caccgccctt	tgctagagt	acacatggaa	ggatttattc	ggaagtgact	2520
tgcttttttg	accatgttac	tcataagatc	cgactatacc	acatacaggg	aatagaagga	2580
cagtctgtgg	aagtttccaa	tattgtggac	atccgaaaag	tatataaccg	tgagattgca	2640
atgaaaattt	cttctgatat	aaaaagccaa	aatagatttt	atactgacct	aaatgggtac	2700
cagattcaac	ctagaatgac	actgagcaaa	ttgcctcttc	aagcaaagt	ctatcccatg	2760
accacaatgg	cctatatcca	ggatgccaaa	catcgtttga	cactgctctc	tgctcagtca	2820
ttaggggttt	cgagtttgaa	tagtgggtcag	attgaagtta	tcattggatcg	aagactcatg	2880
caagatgata	atcgtggcct	tgagcaagg	atccaggata	acaagattac	agctaattcta	2940
tttcgaatac	tactagaaaa	aagaagtgt	gttaatacgg	aagaagaaaa	gaagtcgggtc	3000
agttatcctt	ctctccttag	ccacataact	tcttctctca	tgaatcatcc	agtcattcca	3060
atggcaaata	agttctcttc	acctaccctt	gagctgcaag	gtgaattctc	tccattacag	3120
tcatactttg	cttgtagacat	tcatactgg	aatttgagaa	caatacagtc	aaaggtgggc	3180

EX05-005patentin.txt

```

aatgggcact ccaatgaggc agccttgatc ctccacagaa aagggtttga ttgtcggttc 3240
tctagcaaag gcacagggct gttttgttct actactcagg gaaagatatt ggtacagaaa 3300
cttttaaaaca agtttattgt cgaaagtctc acaccttcac cactatcctt gatgcattca 3360
cctcccggca ctcagaatat aagtgagatc aacttgagtc caatggaaat cagcacattc 3420
cgaatccagt tgagggtgaac ctgactttca catttggttga gagaatcatt ggcttttata 3480
cctttcttgg tttgacgtgc aataaagaag cacattatct tagcttctgg ctactgtgag 3540
aacatgaatt ctgtgattct gtgggttttt tctttttttc ttttaccagt acagtaaga 3599

```

```

<210> 3
<211> 4439
<212> DNA
<213> Homo sapiens

```

```

<400> 3
cactagcgca ttctgcccta caaggcagtg tgaagctact tacatagtat tttcaacagg 60
ttaatccaca cagtgactcc atgaaggaaa taatacaagc attacctcca ttttacaggc 120
aagaaaatag atatttagga agaagaaatt actatcctaa ggtttcacag ttggcacatg 180
atagagtcct ctttcttatt cttttggaga tctaatagata ccataaatga agggttttcc 240
tatgtgttat ttttatagta catgggcagg gtgttttaaa tgtattgaaa tgaattagaa 300
atttttatca tatgatttaa aattgctgtg tgtatcatgt ggtcttgtga tgactcagaa 360
ttccttaaat gactcttctc ttccttcaaa caaaatctta gcagtacccc taaaaatat 420
cagtgtgaaa caccataaca taggttattc cagccaagac tctgagggtga ggacagcttt 480
aaactgttca ggcacattaa aatcaaatca gtggtggaga ttctggcagc tattcaggaa 540
agatgtctct ttagtacatt aaaaaatctt atcccctagt gaggatgatc aggcgtttgg 600
gcatattcct gtctgtggcc agagaacaga ggaaagaatc agttttatca caatgtcagt 660
gctgagcagc acatgactct tttcaaaaac tgtatgtttc ttaatttttc cagggttttt 720
taattcattt atcataaaca cttccaact ttaggaaaca aaatgtatta agatgattgt 780
attttaaaat attcagaggc ctaaaccatt catgacattg atacttaaat ggatatgaga 840
aattttattg caagaaaagg tatactgacc ctcttagctg acttgtcatg tttagtattt 900
ttatttttgc ctgcctatca acaatagctt ctgcagtatc aatttaaatg atacatcaag 960
ctggtaaatg tgagctggcc taccaagtga aagcataact aaatttaaat agctctgata 1020
taaaaataat gaatcagtac atcaaagatt aagaatgcag ttagcaaaaa ttaatgttca 1080
ataaagaagc atgtgtgact ttttaagttag atggtatgtc attcaatgac cagataagga 1140
ctaagttcag gtgcagttta ttcaactgat gtgtgtgttt gaaaaataag acgaaaacat 1200
aatgctttat ttgaataaac ttttaataaaa caatatataa tgtatggaca taaggaaacc 1260
taagtcctcg gggattatag gggaaaccaa ggcatgaggt tacctaaca ggaaccttag 1320
aacataatct tacctggctc agtacacgta ggagagaatg gtagcaggtg aatgggcagt 1380
gagcatggac ctgaggagaa atgaatttgc ctaactttct tgctaaataa atgtgctttt 1440

```

EX05-005patentin.txt

```

ggatgctgac atcgagagag tgggtgtgtga agtaccataa atatttgctt tattgtctgc 1500
gcgggtgtgac tgcattctgc tcatttgcag gtgggcaatg ggcaactcaa tgaggcagcc 1560
ttgatcctcc acagaaaagg gtttgattgt cggttctcta gcaaaggcac agggctgttt 1620
tgttctacta ctcagggaaa gatattggta cagaaacttt taaacaagtt tattgtcgaa 1680
agtctcacac cttcatcact atccttgatg cattcacctc ccggcactca gaatataagt 1740
gagatcaact tgagtccaat ggaaatcagc acattccgaa tccagttgag gtgaacctga 1800
ctttcacatt tggattgaga atcattggct tttatacctt tcttggtttg acgtgcaata 1860
aagaagcaca ttattttagc ttctggctac tgtgagaaca tgaattctgt gattctgtgg 1920
gttttttctt ttttctttta ccagtacagt aagaaaaaaa aaaaaaaaaa aaaagccatg 1980
ctatcaatca agattctttt tttttaaaact ttctcccatg aactaccacc atcagtatga 2040
attgatgcaa caaatgaaga aatatttaaa gacagcctct caacagattg tatctcaggt 2100
taaatagctaa ctaattatgt ctgtgttggg ggttgcaag agattcttaa aagtatctgt 2160
gtgttgatca tcagttttac aaaaacacct atttggctga aatggaataa aatgtttgtg 2220
ggtaaaagct aatggccaaa atggttgcaa tcattcatac tagttagaaa aattatgtgt 2280
tgaaataagt ggaaaagtgc aatccatcca cccttatgat taacgtagat gatttttata 2340
cctttttctg atgtacctct tgaccttctc cttcccttcc taccctttct gagtatttcc 2400
agaaatacct gattttgaat cattcaacag tagaaaaaga ggcatatttt cactacttga 2460
caatgtggga tgggtgcaat ttattccatc ttcactaaaa tagaagcaat tccataggta 2520
ccataaacct attttaggta ccacaagggtg tctttttaca cagctcattt gaatacaggt 2580
gttctgagaa ggggtttcta ttttaaaatt accatatcaa aataaatgtg cttatttttt 2640
ttataagtct tgttaaatca gtgtccatat tactgtttgg ggaaggggga atgttgtggg 2700
gtctgggaga ggggtgggtac tttctatgac acataaattg tgtaattttt gcctgacaat 2760
gctggccaca ttctgatctg tttcattaaa tttgtgggtga tgttactcta aacattttga 2820
ctatttgaat gtactgagat gtcagaaaac aaaacaagga aggaaaatat tgттаattaa 2880
aatgtgctgc tgccaaggaa actgcaactt gaagcaagga ttttgtaaaa tgcaaaatcc 2940
agctactgtt tccatttcac agtagttaac tatattaaag agagaatgct ttaaaattga 3000
tcttgttttg aaacctactt ttatgtagct catcatgggt tatcttacta aggaatatgt 3060
ttgttcattc agttctcaac ttttgtatgt gctaacctta aagtgaagtt ctgagcccat 3120
gtgccattac agtgctttta ataaaattta tttgggatta ttgtttcctt aacattaaaa 3180
taatagcgac atttagacta ttcaatttta gcatagaaag gagtctttga gtatgtacag 3240
ttttgaaaat tctctttgag ataattgatt tcatattctg tggctttcaa cctccattta 3300
cctcttgta ttccaacatc tttatagaga aataaaaacc caatttctct ttcaccattt 3360
agtttgatta tcatctggat tttcactcaa gatgcagctc ctaagattat tgttatgtta 3420
aattcataaa ctccttcacc ttttaataatt aaggaaacaa taccagtgtt gataaagata 3480

```

EX05-005patentin.txt

ttacaagggg	taatttc	catg	caataaacat	gtaccgtaag	ttttcttcca	catat	ttttg	3540
gaaaaaacta	aaaaaagaaa	aaggacttcc	ttttt	gtgga	catctacaga	tgtaggggtt		3600
gccagaagca	aatcccagga	atgagatcag	tatttttcatt	gcattcttaaa	tgtataacct			3660
tcctgtggga	gttcagttt	tctgtgggta	agtgggtgtg	cttaatcatt	ctcgaaattg			3720
tgatcagatg	aaataaaaaa	aaaatcttga	tgcaataaca	gtggttttgc	cacttctggt			3780
tgtttgcgat	ggatctgtcc	catgtcagtc	tggggtttta	ttcagcttgt	gttgctacca			3840
gcagttcaca	ggtaaagcag	aaattctctt	taaccagcaa	gtttctgctt	tttaagggtta			3900
cttttagaat	aatcatcag	ggaaacagag	aggatgcttt	gctttgggtt	gtagtcaaaa			3960
actgat	ttaaa	taattta	atg	tctctggcac	acactaaaaa	ccatacactt	cagttgtgat	4020
ctcag	tgga	tatttat	ttt	gtaggtttc	gttacattta	ttattacaga	tgttcagttg	4080
accaagtagt	tcagtgtttt	ctttcctttt	tttggaatt	ttagtttgag	tttgtgactg			4140
cagtgttcaa	gaactcagca	tccttgtttt	ctacaaatac	tgattaaaaat	aaaatgctgt			4200
aaaatgtgat	gtaaaacatt	atcatgatct	tcccatgcct	ttgttgact	tgtgccgaag			4260
tgttttgata	ttcctttgtc	tggaagaaaa	tgtttgcttt	cattttgatc	attttgttca			4320
ccttggaatc	aacagggtttt	gatattttct	cttggaagat	tttatatctt	tttggaata			4380
tgtaataataa	gatctcta	aat	aaaagataat	cttatcatgt	aagaaaaaaa	aaaaaaaaa		4439

<210> 4
 <211> 4917
 <212> DNA
 <213> Homo sapiens

<400> 4	ggcagctcgg	ccgactgggc	ccggagcggc	gcggaggccg	ggcgctgacg	gtgtgtgtgg	60
	aggccagtat	gaagctgaaa	aagcagggtga	cagtgtgtgg	ggctgccatc	ttctgtgtgg	120
	cagtccttctc	gctctacctc	atgctggacc	gagtgcaca	cgatcccacc	cgacaccaga	180
	atggtgggaa	cttcccccg	agccaaattt	ctgtgctgca	gaaccgcatt	gagcagctgg	240
	agcagctttt	ggaggagaac	catgagatta	tcagccatat	caaggactcc	gtgctggagc	300
	tgacagccaa	cgcagagggc	ccgcccgcga	tgctgcccta	ctacacggtc	aatggctcct	360
	gggtggtgcc	accggagccc	cggcccagct	tcttctccat	ctccccgcag	gactgccagt	420
	ttgctttggg	gggccggggg	cagaagccag	agctgcagat	gctcactgtg	tcggaggagc	480
	tgccgtttga	caacgtggat	ggtggtgtgt	ggaggcaagg	cttcgacatc	tcctacgacc	540
	cgcacgactg	ggatgctgaa	gacctgcagg	tgtttgtgg	gccccactct	cacaatgacc	600
	caggctggat	caagaccttt	gacaagtact	acacagagca	gaccaaacac	atcctcaata	660
	gcatggtgtc	taagctgcag	gaggacccc	ggcggcgctt	cctctgggca	gaggctctcct	720
	tcttcgccaa	gtggtgggac	aacatcaatg	tccaaaagag	agcggcagtc	cgaaggctgg	780
	tgggaaacgg	gcagctggag	attgcgacag	gaggctgggt	gatgccagat	gaggccaatt	840

EX05-005patentin.txt

```

cccactactt tgcattgatt gaccagctca tcgaaggaca ccagtggctg gagagaaatc 900
ttggtgcaac cccccgctct ggctgggcag tggacccctt tggatacagc tccaccatgc 960
cttacctgct gcgccgtgcc aacctcacca gcatgctgat tcagagagtg cactatgcca 1020
tcaagaagca ctttgctgcc acccacagcc tagagttcat gtggaggcag acatgggact 1080
cggactccag cacagacatc ttctgtcaca tgatgccctt ctacagctat gacgtcccc 1140
atacctgtgg ccagatccc aagatctgct gccaatgtga tttcaaacgc ctgcctgggtg 1200
ggcgcatcaa ctgcccttgg aagggtgccac cccgggccat cacagaggcc aacgtggcag 1260
agagggcagc cctgcttctg gaccaatacc ggaagaagtc ccagctgttc cgaagcaacg 1320
tcctcctggt gcctccttga gatgacttcc gatatgacaa gcccaggag tgggatgccc 1380
agttcttcaa ctaccaacgg ctctttgact tcttcaacag caggcctaac ctccatgtgc 1440
aggcccagtt tggcactctt tctgactatt ttgatgccct gtacaagagg acaggggtgg 1500
agccaggggc ccggcctcca gggtttcctg tgctgagcgg ggatttcttc tcctatgcgg 1560
accgggagga tcattactgg acaggctatt acacttcccg gcccttctac aagagcttag 1620
accgagtcct ggaagcccac ctgcgggggg cagaggttct gtacagcctg gctgcagctc 1680
acgctcgccg ctctgggtctg gctggccggt acccactgtc tgatttcacc ctccctgacgg 1740
aagctcggcg cacattgggg ctcttcacg atcacgatgc catcactggc acggccaagg 1800
aggctgtggt ggtggactat ggggtcaggc ttctgcgctc cttgtcaac ctgaagcagg 1860
tcatcattca tgcagcccac tatctgggtg tgggggacaa ggagacctac cactttgacc 1920
ctgaggcgcc ctctctcaa gtggatgaca ctgccttaag tcacgacgcc ctcccagagc 1980
gcacggtgat ccagctggat tcctcgccca gggttggtggt cctattcaac cactggaac 2040
aggagcgatt cagcatggtg tccctgctgg tcaactctcc ccgctgctg gtcctttcgg 2100
aggagggtca gcccctggcc gtgcagatca gcgcacactg gagctctgcc accgaggcgg 2160
tcctgacgt ctaccagggt tctgtgctg tccgctgcc agccctgggc ctgggcgtgc 2220
tgcagctaca gctgggcctg gatgggcacc gcacgctgcc ctctctgtg cgcatctacc 2280
tgcacggccg gcagctgtcc gtcagcaggc acgaagcgtt tcctctccgt gtcattgact 2340
ctggcaccag cgacttcgcc ctacgaacc gctacatgca ggtctggttc tcaggcctta 2400
ctgggctcct caaggggtca gggctgtgtt ttttggcaga gcatccgaag ggtggatgag 2460
gagcacgagc agcagggtga catgcaggtc cttgtctatg gcacccgtac gtccaaagac 2520
aagagtggag cctacctctt cctgcccgat ggcgaggcaa gccctacgtc cccaaggagc 2580
ccccgtgct gcgtgtcact gaaggccctt tcttctcaga ggtggttgcg tactatgagc 2640
acattcacca ggcggtccgg ctttacaatc tgccaggggt ggaggggctg tctctggaca 2700
tatcatccct ggtggacatc cgggactacg tcaacaagga gctggccctg cacatccata 2760
cagacatcga cagccagggt gcagccccga cggtatctga agaagctccc cctccaggcc 2820
aacttctacc ccatgccagt catggcctat atccaggacg cacagaagcg cctcacgctg 2880

```

EX05-005patentin.txt

cacactgccc	agggcctggg	tgtctctagc	ctcaaagatg	gccagctgga	ggtgatcttg	2940
gaccggcggc	tgatgcagga	tgacaaccgg	ggcctaggcc	aagggctcaa	ggacaacaag	3000
agaacctgca	accgtttccg	cctcctgcta	gagcggcgaa	ccgtgggcag	tgaggtccaa	3060
gatagccact	ctaccagcta	cccattccctc	ctcagccacc	tgacctccat	gtacctgaac	3120
gccccggcgc	tcgctctgcc	tgtagccagg	atgcagctcc	caggccctgg	tctgcgctca	3180
tttcatcctc	tggcttcctc	actgccctgt	gacttccacc	tgctcaacct	acgtacgctc	3240
caggctgagg	aggacaccct	accctcgggc	gagaccgcac	tcattcttaca	ccgcaagggg	3300
tttgactgcg	gcctggaggc	caagaacttg	ggcttcaact	gcaccacaag	ccaaggcaag	3360
gtagccctgg	gcagcctttt	ccatggcctg	gatgtggtat	tccttcagcc	aacctccttg	3420
acgttactgt	accctctggc	ctccccgtcc	aacagcactg	acgtctattt	ggagcccatg	3480
gagattgcta	cctttcgctc	ccgcttgggt	tagggcttct	tgtggcctga	agagaaagtt	3540
cattcacaga	gactgcctct	taacatgaag	atcattggac	aagccacacg	ggtatcccat	3600
cccgatctgc	ctcccagaac	tgtgacacac	tgggctctgc	cctcattttc	tgtttattgc	3660
tgtgctgtg	ttttcggcgc	aaccacaaaa	cccagtgatg	ggtaaataag	gcagacgcca	3720
gtgagatcag	ggagagaagg	cccttggtca	gagtgggcag	tgccaggctc	tgctttgggt	3780
tgtgagtgga	cacccaactg	ggcacaggct	caggcaccca	tcctttttcc	aaacagggat	3840
atagaagtgg	tggaagcaga	cagaagaggt	aagggaggct	aagtgggtaa	cagcccagca	3900
tcagggtcac	tgtggcaaca	gcaggctcta	ggggaatcct	gtggttatgt	agagactcca	3960
tgtcctgggt	tgatgagcag	gatcagagt	actctgggag	gacaggggtg	gggaccaga	4020
gttagcagt	gggatggagc	agtagaagga	atcactgttt	ctcctaggag	tctgaaggcc	4080
tcgctgcttt	ctgtgatggc	tttgcagtaa	gtgccgcctg	gcctgcatgc	attggctaac	4140
aggctgcaga	atggcaggaa	ggactcgcta	gagattgtca	tgccagaga	tcataggtca	4200
cttcaggtag	caagaccctt	ggcaaactgg	gcacttggcc	tatgtactga	tttgtgggat	4260
ggtggcaggg	gtgtggggtc	cttcaccctg	cctgaattct	ctttggcttc	tgtgctctgt	4320
atgctgctgt	ccccaaaggc	tctttcttat	tatggcaggg	agtggggatt	ggtcctactt	4380
tctttctctg	gaaaggaaag	cctccaagac	tccatgtgct	tgggcagctt	gagaaggcgt	4440
tcagcaccac	gcctagcagg	cagaccttga	agcctcacct	ttagtctatc	tgagaggta	4500
ttcagttcct	ggcacagggg	actaggggca	tgtagagtat	atgaggaggc	agtatggctg	4560
tgagggagcc	ttcatttcag	cttcaattaa	tagggaagaa	tttatgatag	ctctatagat	4620
gctgaaaagg	tatttcgtaa	gattttaaata	ccatccctta	ttaaaactct	tagtaaatta	4680
agtctggaaa	gaaacaccct	aatctagata	aaggtctgtt	tcagaaacca	acagtgatgg	4740
cattctaaag	agtcagacgc	cacaggcatt	cccattaaag	tcagaaacta	gccaagggca	4800
agctattatt	cagcagtgtc	ccggcactac	taacccttgc	aacaagccag	atgaggaaca	4860
taaggaagaa	ttataattgt	cattattttgt	agacaataaa	actgcctacc	tgtaaaa	4917

EX05-005patentin.txt

<210> 5
 <211> 1143
 <212> PRT
 <213> Homo sapiens

<400> 5

Met Lys Leu Ser Arg Gln Phe Thr Val Phe Gly Ser Ala Ile Phe Cys
 1 5 10 15

Val Val Ile Phe Ser Leu Tyr Leu Met Leu Asp Arg Gly His Leu Asp
 20 25 30

Tyr Pro Arg Asn Pro Arg Arg Glu Gly Ser Phe Pro Gln Gly Gln Leu
 35 40 45

Ser Met Leu Gln Glu Lys Ile Asp His Leu Glu Arg Leu Leu Ala Glu
 50 55 60

Asn Asn Glu Ile Ile Ser Asn Ile Arg Asp Ser Val Ile Asn Leu Ser
 65 70 75 80

Glu Ser Val Glu Asp Gly Pro Lys Ser Ser Gln Ser Asn Phe Ser Gln
 85 90 95

Gly Ala Gly Ser His Leu Leu Pro Ser Gln Leu Ser Leu Ser Val Asp
 100 105 110

Thr Ala Asp Cys Leu Phe Ala Ser Gln Ser Gly Ser His Asn Ser Asp
 115 120 125

Val Gln Met Leu Asp Val Tyr Ser Leu Ile Ser Phe Asp Asn Pro Asp
 130 135 140

Gly Gly Val Trp Lys Gln Gly Phe Asp Ile Thr Tyr Glu Ser Asn Glu
 145 150 155 160

Trp Asp Thr Glu Pro Leu Gln Val Phe Val Val Pro His Ser His Asn
 165 170 175

Asp Pro Gly Trp Leu Lys Thr Phe Asn Asp Tyr Phe Arg Asp Lys Thr
 180 185 190

Gln Tyr Ile Phe Asn Asn Met Val Leu Lys Leu Lys Glu Asp Ser Arg
 195 200 205

Arg Lys Phe Ile Trp Ser Glu Ile Ser Tyr Leu Ser Lys Trp Trp Asp
 210 215 220

Ile Ile Asp Ile Gln Lys Lys Asp Ala Val Lys Ser Leu Ile Glu Asn
 225 230 235 240

EX05-005patentin.txt

Gly Gln Leu Glu Ile Val Thr Gly Gly Trp Val Met Pro Asp Glu Ala
 245 250 255
 Thr Pro His Tyr Phe Ala Leu Ile Asp Gln Leu Ile Glu Gly His Gln
 260 265 270
 Trp Leu Glu Asn Asn Ile Gly Val Lys Pro Arg Ser Gly Trp Ala Ile
 275 280 285
 Asp Pro Phe Gly His Ser Pro Thr Met Ala Tyr Leu Leu Asn Arg Ala
 290 295 300
 Gly Leu Ser His Met Leu Ile Gln Arg Val His Tyr Ala Val Lys Lys
 305 310 315 320
 His Phe Ala Leu His Lys Thr Leu Glu Phe Phe Trp Arg Gln Asn Trp
 325 330 335
 Asp Leu Gly Ser Val Thr Asp Ile Leu Cys His Met Met Pro Phe Tyr
 340 345 350
 Ser Tyr Asp Ile Pro His Thr Cys Gly Pro Asp Pro Lys Ile Cys Cys
 355 360 365
 Gln Phe Asp Phe Lys Arg Leu Pro Gly Gly Arg Phe Gly Cys Pro Trp
 370 375 380
 Gly Val Pro Pro Glu Thr Ile His Pro Gly Asn Val Gln Ser Arg Ala
 385 390 395 400
 Arg Met Leu Leu Asp Gln Tyr Arg Lys Lys Ser Lys Leu Phe Arg Thr
 405 410 415
 Lys Val Leu Leu Ala Pro Leu Gly Asp Asp Phe Arg Tyr Cys Glu Tyr
 420 425 430
 Thr Glu Trp Asp Leu Gln Phe Lys Asn Tyr Gln Gln Leu Phe Asp Tyr
 435 440 445
 Met Asn Ser Gln Ser Lys Phe Lys Val Lys Ile Gln Phe Gly Thr Leu
 450 455 460
 Ser Asp Phe Phe Asp Ala Leu Asp Lys Ala Asp Glu Thr Gln Arg Asp
 465 470 475 480
 Lys Gly Gln Ser Met Phe Pro Val Leu Ser Gly Asp Phe Phe Thr Tyr
 485 490 495
 Ala Asp Arg Asp Asp His Tyr Trp Ser Gly Tyr Phe Thr Ser Arg Pro
 500 505 510

EX05-005patentin.txt

Phe Tyr Lys Arg Met Asp Arg Ile Met Glu Ser His Leu Arg Ala Ala
 515 520 525

Glu Ile Leu Tyr Tyr Phe Ala Leu Arg Gln Ala His Lys Tyr Lys Ile
 530 535 540

Asn Lys Phe Leu Ser Ser Ser Leu Tyr Thr Ala Leu Thr Glu Ala Arg
 545 550 555 560

Arg Asn Leu Gly Leu Phe Gln His His Asp Ala Ile Thr Gly Thr Ala
 565 570 575

Lys Asp Trp Val Val Val Asp Tyr Gly Thr Arg Leu Phe His Ser Leu
 580 585 590

Met Val Leu Glu Lys Ile Ile Gly Asn Ser Ala Phe Leu Leu Ile Leu
 595 600 605

Lys Asp Lys Leu Thr Tyr Asp Ser Tyr Ser Pro Asp Thr Phe Leu Glu
 610 615 620

Met Asp Leu Lys Gln Lys Ser Gln Asp Ser Leu Pro Gln Lys Asn Ile
 625 630 635 640

Ile Arg Leu Ser Ala Glu Pro Arg Tyr Leu Val Val Tyr Asn Pro Leu
 645 650 655

Glu Gln Asp Arg Ile Ser Leu Val Ser Val Tyr Val Ser Ser Pro Thr
 660 665 670

Val Gln Val Phe Ser Ala Ser Gly Lys Pro Val Glu Val Gln Val Ser
 675 680 685

Ala Val Trp Asp Thr Ala Asn Thr Ile Ser Glu Thr Ala Tyr Glu Ile
 690 695 700

Ser Phe Arg Ala His Ile Pro Pro Leu Gly Leu Lys Val Tyr Lys Ile
 705 710 715 720

Leu Glu Ser Ala Ser Ser Asn Ser His Leu Ala Asp Tyr Val Leu Tyr
 725 730 735

Lys Asn Lys Val Glu Asp Ser Gly Ile Phe Thr Ile Lys Asn Met Ile
 740 745 750

Asn Thr Glu Glu Gly Ile Thr Leu Glu Asn Ser Phe Val Leu Leu Arg
 755 760 765

Phe Asp Gln Thr Gly Leu Met Lys Gln Met Met Thr Lys Glu Asp Gly
 770 775 780

EX05-005patentin.txt

Lys His His Glu Val Asn Val Gln Phe Ser Trp Tyr Gly Thr Thr Ile
 785 790 795 800

Lys Arg Asp Lys Ser Gly Ala Tyr Leu Phe Leu Pro Asp Gly Asn Ala
 805 810 815

Lys Pro Tyr Val Tyr Thr Thr Pro Pro Phe Val Arg Val Thr His Gly
 820 825 830

Arg Ile Tyr Ser Glu Val Thr Cys Phe Phe Asp His Val Thr His Arg
 835 840 845

Val Arg Leu Tyr His Ile Gln Gly Ile Glu Gly Gln Ser Val Glu Val
 850 855 860

Ser Asn Ile Val Asp Ile Arg Lys Val Tyr Asn Arg Glu Ile Ala Met
 865 870 875 880

Lys Ile Ser Ser Asp Ile Lys Ser Gln Asn Arg Phe Tyr Thr Asp Leu
 885 890 895

Asn Gly Tyr Gln Ile Gln Pro Arg Met Thr Leu Ser Lys Leu Pro Leu
 900 905 910

Gln Ala Asn Val Tyr Pro Met Thr Thr Met Ala Tyr Ile Gln Asp Ala
 915 920 925

Lys His Arg Leu Thr Leu Leu Ser Ala Gln Ser Leu Gly Val Ser Ser
 930 935 940

Leu Asn Ser Gly Gln Ile Glu Val Ile Met Asp Arg Arg Leu Met Gln
 945 950 955 960

Asp Asp Asn Arg Gly Leu Glu Gln Gly Ile Gln Asp Asn Lys Ile Thr
 965 970 975

Ala Asn Leu Phe Arg Ile Leu Leu Glu Lys Arg Ser Ala Val Asn Thr
 980 985 990

Glu Glu Glu Lys Lys Ser Val Ser Tyr Pro Ser Leu Leu Ser His Ile
 995 1000 1005

Thr Ser Ser Leu Met Asn His Pro Val Ile Pro Met Ala Asn Lys
 1010 1015 1020

Phe Ser Pro Thr Leu Glu Leu Gln Gly Glu Phe Ser Pro Leu Gln
 1025 1030 1035

Ser Ser Leu Pro Cys Asp Ile His Leu Val Asn Leu Arg Thr Ile
 1040 1045 1050

EX05-005patentin.txt

Gln Ser Lys Val Gly Asn Gly His Ser Asn Glu Ala Ala Leu Ile
 1055 1060 1065

Leu His Arg Lys Gly Phe Asp Cys Arg Phe Ser Ser Lys Gly Thr
 1070 1075 1080

Gly Leu Phe Cys Ser Thr Thr Gln Gly Lys Ile Leu Val Gln Lys
 1085 1090 1095

Leu Leu Asn Lys Phe Ile Val Glu Ser Leu Thr Pro Ser Ser Leu
 1100 1105 1110

Ser Leu Met His Ser Pro Pro Gly Thr Gln Asn Ile Ser Glu Ile
 1115 1120 1125

Asn Leu Ser Pro Met Glu Ile Ser Thr Phe Arg Ile Gln Leu Arg
 1130 1135 1140

<210> 6
 <211> 1139
 <212> PRT
 <213> Homo sapiens

<400> 6

Met Lys Leu Lys Lys Gln Val Thr Val Cys Gly Ala Ala Ile Phe Cys
 1 5 10 15

Val Ala Val Phe Ser Leu Tyr Leu Met Leu Asp Arg Val Gln His Asp
 20 25 30

Pro Thr Arg His Gln Asn Gly Gly Asn Phe Pro Arg Ser Gln Ile Ser
 35 40 45

Val Leu Gln Asn Arg Ile Glu Gln Leu Glu Gln Leu Leu Glu Glu Asn
 50 55 60

His Glu Ile Ile Ser His Ile Lys Asp Ser Val Leu Glu Leu Thr Ala
 65 70 75 80

Asn Ala Glu Gly Pro Pro Ala Met Leu Pro Tyr Tyr Thr Val Asn Gly
 85 90 95

Ser Trp Val Val Pro Pro Glu Pro Arg Pro Ser Phe Phe Ser Ile Ser
 100 105 110

Pro Gln Asp Cys Gln Phe Ala Leu Gly Gly Arg Gly Gln Lys Pro Glu
 115 120 125

Leu Gln Met Leu Thr Val Ser Glu Glu Leu Pro Phe Asp Asn Val Asp
 130 135 140

Gly Gly Val Trp Arg Gln Gly Phe Asp Ile Ser Tyr Asp Pro His Asp

EX05-005patentin.txt

145	150	155	160
Trp Asp Ala Glu Asp 165	Leu Gln Val Phe Val 170	Val Val Pro His Ser His 175	Asn
Asp Pro Gly Trp 180	Ile Lys Thr Phe Asp 185	Lys Tyr Tyr Thr Glu 190	Gln Thr
Gln His Ile 195	Leu Asn Ser Met Val 200	Ser Lys Leu Gln Glu 205	Asp Pro Arg
Arg Arg Phe 210	Leu Trp Ala Glu 215	Val Ser Phe Phe Ala 220	Lys Trp Trp Asp
Asn Ile Asn Val 225	Gln Lys Arg Ala Ala 230	Val Arg Arg Leu Val 235	Gly Asn 240
Gly Gln Leu Glu 245	Ile Ala Thr Gly Gly 250	Trp Val Met Pro Asp 255	Glu Ala
Asn Ser His Tyr 260	Phe Ala Leu Ile Asp 265	Gln Leu Ile Glu Gly 270	His Gln
Trp Leu Glu 275	Arg Asn Leu Gly Ala 280	Thr Pro Arg Ser Gly 285	Trp Ala Val
Asp Pro Phe 290	Gly Tyr Ser Ser 295	Thr Met Pro Tyr Leu 300	Leu Arg Arg Ala
Asn Leu Thr 305	Ser Met Leu Ile 310	Gln Arg Val His 315	Tyr Ala Ile Lys Lys 320
His Phe Ala Ala 325	Thr His Ser Leu Glu 330	Phe Met Trp Arg Gln 335	Thr Trp
Asp Ser Asp 340	Ser Ser Thr Asp Ile 345	Phe Cys His Met Met 350	Pro Phe Tyr
Ser Tyr Asp 355	Val Pro His Thr Cys 360	Gly Pro Asp Pro Lys 365	Ile Cys Cys
Gln Phe 370	Asp Phe Lys Arg Leu 375	Pro Gly Gly Arg Ile 380	Asn Cys Pro Trp
Lys Val 385	Pro Pro Arg Ala 390	Ile Thr Glu Ala Asn 395	Val Ala Glu Arg Ala 400
Ala Leu Leu Leu 405	Asp Gln Tyr Arg Lys 410	Lys Ser Gln Leu Phe 415	Arg Ser
Asn Val Leu Leu Val 420	Pro Leu Gly Asp Asp 425	Phe Arg Tyr Asp Lys 430	Pro

EX05-005patentin.txt

420

425

430

Gln Glu Trp Asp Ala Gln Phe Phe Asn Tyr Gln Arg Leu Phe Asp Phe
 435 440 445

Phe Asn Ser Arg Pro Asn Leu His Val Gln Ala Gln Phe Gly Thr Leu
 450 455 460

Ser Asp Tyr Phe Asp Ala Leu Tyr Lys Arg Thr Gly Val Glu Pro Gly
 465 470 475 480

Ala Arg Pro Pro Gly Phe Pro Val Leu Ser Gly Asp Phe Phe Ser Tyr
 485 490 495

Ala Asp Arg Glu Asp His Tyr Trp Thr Gly Tyr Tyr Thr Ser Arg Pro
 500 505 510

Phe Tyr Lys Ser Leu Asp Arg Val Leu Glu Ala His Leu Arg Gly Ala
 515 520 525

Glu Val Leu Tyr Ser Leu Ala Ala Ala His Ala Arg Arg Ser Gly Leu
 530 535 540

Ala Gly Arg Tyr Pro Leu Ser Asp Phe Thr Leu Leu Thr Glu Ala Arg
 545 550 555 560

Arg Thr Leu Gly Leu Phe Gln His His Asp Ala Ile Thr Gly Thr Ala
 565 570 575

Lys Glu Ala Val Val Val Asp Tyr Gly Val Arg Leu Leu Arg Ser Leu
 580 585 590

Val Asn Leu Lys Gln Val Ile Ile His Ala Ala His Tyr Leu Val Leu
 595 600 605

Gly Asp Lys Glu Thr Tyr His Phe Asp Pro Glu Ala Pro Phe Leu Gln
 610 615 620

Val Asp Asp Thr Arg Leu Ser His Asp Ala Leu Pro Glu Arg Thr Val
 625 630 635 640

Ile Gln Leu Asp Ser Ser Pro Arg Phe Val Val Leu Phe Asn Pro Leu
 645 650 655

Glu Gln Glu Arg Phe Ser Met Val Ser Leu Leu Val Asn Ser Pro Arg
 660 665 670

Val Arg Val Leu Ser Glu Glu Gly Gln Pro Leu Ala Val Gln Ile Ser
 675 680 685

Ala His Trp Ser Ser Ala Thr Glu Ala Val Pro Asp Val Tyr Gln Val

EX05-005patentin.txt
700

690

695

Ser Val Pro Val Arg Leu Pro Ala Leu Gly Leu Gly Val Leu Gln Leu
 705 710 715 720
 Gln Leu Gly Leu Asp Gly His Arg Thr Leu Pro Ser Ser Val Arg Ile
 725 730 735
 Tyr Leu His Gly Arg Gln Leu Ser Val Ser Arg His Glu Ala Phe Pro
 740 745 750
 Leu Arg Val Ile Asp Ser Gly Thr Ser Asp Phe Ala Leu Ser Asn Arg
 755 760 765
 Tyr Met Gln Val Trp Phe Ser Gly Leu Thr Gly Leu Leu Lys Ser Ile
 770 775 780
 Arg Arg Val Asp Glu Glu His Glu Gln Gln Val Asp Met Gln Val Leu
 785 790 795 800
 Val Tyr Gly Thr Arg Thr Ser Lys Asp Lys Ser Gly Ala Tyr Leu Phe
 805 810 815
 Leu Pro Asp Gly Glu Ala Ser Pro Thr Ser Pro Arg Ser Pro Pro Cys
 820 825 830
 Cys Val Ser Leu Lys Ala Leu Ser Ser Gln Arg Trp Leu Arg Thr Met
 835 840 845
 Ser Thr Phe Thr Arg Arg Ser Gly Phe Thr Ile Cys Gln Gly Trp Arg
 850 855 860
 Gly Cys Leu Trp Thr Tyr His Pro Trp Trp Thr Ser Gly Thr Thr Ser
 865 870 875 880
 Thr Arg Ser Trp Pro Cys Thr Ser Ile Gln Thr Ser Thr Ala Arg Val
 885 890 895
 Gln Pro Arg Arg Tyr Leu Lys Lys Leu Pro Leu Gln Ala Asn Phe Tyr
 900 905 910
 Pro Met Pro Val Met Ala Tyr Ile Gln Asp Ala Gln Lys Arg Leu Thr
 915 920 925
 Leu His Thr Ala Gln Ala Leu Gly Val Ser Ser Leu Lys Asp Gly Gln
 930 935 940
 Leu Glu Val Ile Leu Asp Arg Arg Leu Met Gln Asp Asp Asn Arg Gly
 945 950 955 960
 Leu Gly Gln Gly Leu Lys Asp Asn Lys Arg Thr Cys Asn Arg Phe Arg

EX05-005patentin.txt
970

965

975

Leu Leu Leu Glu Arg Arg Thr Val Gly Ser Glu Val Gln Asp Ser His
 980 985 990

Ser Thr Ser Tyr Pro Ser Leu Leu Ser His Leu Thr Ser Met Tyr Leu
 995 1000 1005

Asn Ala Pro Ala Leu Ala Leu Pro Val Ala Arg Met Gln Leu Pro
 1010 1015 1020

Gly Pro Gly Leu Arg Ser Phe His Pro Leu Ala Ser Ser Leu Pro
 1025 1030 1035

Cys Asp Phe His Leu Leu Asn Leu Arg Thr Leu Gln Ala Glu Glu
 1040 1045 1050

Asp Thr Leu Pro Ser Ala Glu Thr Ala Leu Ile Leu His Arg Lys
 1055 1060 1065

Gly Phe Asp Cys Gly Leu Glu Ala Lys Asn Leu Gly Phe Asn Cys
 1070 1075 1080

Thr Thr Ser Gln Gly Lys Val Ala Leu Gly Ser Leu Phe His Gly
 1085 1090 1095

Leu Asp Val Val Phe Leu Gln Pro Thr Ser Leu Thr Leu Leu Tyr
 1100 1105 1110

Pro Leu Ala Ser Pro Ser Asn Ser Thr Asp Val Tyr Leu Glu Pro
 1115 1120 1125

Met Glu Ile Ala Thr Phe Arg Leu Arg Leu Gly
 1130 1135

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US05/03483

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : G01N 33/53, 33/566

US CL : 435/7.1; 436/501

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/7.1; 436/501

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KANG et al., Retinoic acid alters the intracellular trafficking of the mannose-6-phosphate/insulin-like growth factor II receptor and lysosomal enzymes. Proceedings of the National Academy of Sciences, USA, Cell Biology, Volume 95, November 1998, pages 13687-13691, see entire document.	1-25

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

27 April 2005 (27.04.2005)

Date of mailing of the international search report

12 MAY 2005

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Lisa V. Daniels-Cook

Telephone No. (571) 272-1600

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US05/03483

Continuation of B. FIELDS SEARCHED Item 3:

East and West patent database search

STN-biosis, caplus, embase, medline, cancerlit, japio

Pam Inventor Search